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ABSTRACT
The prohibitory effects of dietary fiber in colorectal cancer have been
identified, although the detailed mechanism of this beneficial effect remain
unclear. Butyrate, a fermentation metabolite of fiber, has anti-cancer properties
by inhibiting cell proliferation and increasing cell apoptosis in cancer cells. A
major mechanism, whereby butyrate exerts anti-cancer effects in colorectal
cancer, is its role as an HDAC inhibitor. Moreover, it has been suggested that the
metabolic fate of butyrate is significantly related to its role as an HDAC inhibitor.
Therefore, understanding butyrate metabolism in cancerous colonocytes sheds
important light on how butyrate has its selective and inhibitory effects toward
colorectal cancer.
This dissertation reports (1) colorectal cancer cells exhibit reduced ability
to oxidize butyrate; (2) the mechanisms of butyrate oxidation are carnitinedependent and carnitine-independent in colorectal cancer cells; (3) the Warburg
effect, inactivation of pyruvate dehydrogenase (PDH), is a critical event to
repress the carnitine-dependent butyrate oxidation in colorectal cancer cells.
Also, this dissertation further describes that (1) butyrate suppresses its own
oxidation by regulating short-chain acyl dehydrogenase (SCAD) levels in
colorectal cancer cells; (2) butyrate acts as an HDAC inhibitor and (3) selectively
inhibits HDAC 1 in order to suppress SCAD expression in colorectal cancer cells.
These findings bridge the important relationship between butyrate
metabolism and its epigenetic role in order to explain its inhibitory effects in
colorectal cancer cells. Also, the results raise a key question (Why is butyrate
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regulation in its own oxidation in colorectal cancer cells?) for future studies that
may discover other mechanisms of the preventive effects of butyrate in colorectal
cancer.
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INTRODUCTION
Colorectal cancer (CRC) is the third most commonly diagnosed and mortal
cancer in the United States (American Cancer Society, 2016). The approximate
economic burden of CRC including drug therapy is up to $40,000 per month
(Latremouille-Viau et al., 2016; Meropol & Schulman, 2007). Most risk factors of
CRC are highly associated with modifiable lifestyles, such as diet, alcohol
consumption, smoking, physical activity and obesity (Johnson et al., 2013). Of
these risk factors, dietary factors play a significant role in CRC incidence, and the
modifications of food patterns might decrease CRC risk up to 70% (Haggar &
Boushey, 2009).
The protective function of dietary fiber has been emphasized through
many epidemiological, clinical and experimental studies, even though it is
controversial. A diet high in dietary fiber (DF) has a beneficial impact on colon
health and is proposed to decrease the likelihood of developing (Blackwood,
Salter, Dettmar, & Chaplin, 2000; Liu, 2003; Mudgil & Barak, 2013; Vargas &
Thompson, 2012). Currently, the critical roles of the gut microbiota and its
derived metabolites toward colonic health and CRC development has been the
main focus in CRC research (Holmes, Li, Athanasiou, Ashrafian, & Nicholson,
2011; Louis, Hold, & Flint, 2014). DF escapes digestion in the small intestine and
is metabolized in the colon by gut microbiota (Gropper & Smith, 2012; Tungland
& Meyer, 2002). Through fermentation, DF gives rise to short chain fatty acids
(SCFAs) and gases as end-products that have various advantageous roles for
colonic and host health (Blackwood et al., 2000; Macfarlane & Macfarlane, 2012).
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Among the microbial-derived metabolites, butyrate plays an important role
in colonic health and has anti-cancer effects (Havenaar, 2011). Primarily,
butyrate is the preferred energy substrate for colonocytes and also functions as a
histone deacetylase (HDAC) inhibitor (Hamer et al., 2008). As an HDAC inhibitor,
butyrate causes epigenetic modifications of genes involved in cell proliferation,
apoptosis and differentiation and reduces growth of tumor cells (Leonel &
Alvarez-Leite, 2012; Tan et al., 2014). However, the obvious opposing roles of
butyrate in cell proliferation in normal versus cancerous colonocytes has been
observed and referred to as the “butyrate paradox” (Hague, Singh, & Paraskeva,
1997; Leonel & Alvarez-Leite, 2012). Recent evidence indicates that the
metabolic transformation of cancerous colonocytes to utilize more glucose over
butyrate (the Warburg effect) results in a change of butyrate’s metabolic fate and
function (Bultman, 2014; Donohoe, Curry, & Bultman, 2013). Also, a more
complicated role of butyrate in histone acetylation has been described (Donohoe
et al., 2012). If butyrate is oxidized as an energy source, it is involved in histone
acetylation as a cofactor for histone acetyltransferase (HAT). However, if
butyrate is accumulated in the nucleus due to the Warburg effect, it acts as an
HDAC inhibitor.
Recent evidence has also shown that reduced gene expression that
related to mitochondrial metabolism in the tumor tissue from CRC patients might
bring the change of butyrate metabolism in cancerous colonocytes (BirkenkampDemtroder et al., 2002). For example, short-chain acyl-CoA dehydrogenase
(SCAD), an enzyme functioning associated with the first step of butyrate
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oxidation is decreased in CRC. This may allude to a reduced ability in cancerous
colonocytes to oxidize butyrate, which would also impact the molecule’s
epigenetic roles. Therefore, a better understanding of mechanisms that regulate
butyrate oxidation in cancerous colonocytes is necessary to unravel how butyrate
exerts its selective and inhibitory effects toward colorectal cancer. However,
there has been less understanding regarding the mechanism of butyrate
oxidation in cancerous colonocytes and the link between SCAD and butyrate
oxidation in cancerous colonocytes.
Thus, this dissertation begins with general information about CRC, the role
of dietary fiber in CRC, and overall knowledge about butyrate. Chapter II focuses
on the mechanisms of butyrate oxidation in cancerous colonocytes by
emphasizing carnitine-dependent oxidation mechanisms. Chapter III focuses on
butyrate’s function in its own metabolism in cancerous colonocytes by describing
the role of SCAD.

3

CHAPTER I
LITERATURE REVIEW
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1.1 Colorectal cancer
Colorectal cancer (CRC) is one of the most common and deadly cancers
worldwide, along with lung, breast and prostate cancer (Arnold et al., 2015;
Siegel, Miller, & Jemal, 2016). In 2016, the American Cancer Society expects
16% new CRC cases and deaths in the United States (Siegel et al., 2016). The
causes of CRC are most likely associated with an individual’s lifestyle, which
includes diet, alcohol consumption, physical activity and smoking (Arnold et al.,
2015; Arnold et al., 2016; Patel & De, 2016). Therefore, an understanding of the
pathology and risk factors associated with CRC are critical components in the
fight to decrease CRC incidence and mortality. Section 1 will provide
comprehensive background about CRC (including a general introduction,
molecular approach of carcinogenesis and risk factors).
1.1.1. General Introduction: Definition, Stages and Diagnosis of CRC
Colorectal cancer is the development of malignant cells in the colon and/or
rectum (NCI, 2014). The TNM classification of malignant tumors (TNM) classifies
CRC into four stages (Edge SB et al., 2010): Stage I - cancer has dispersed to
submucosa and slightly invaded the muscle layer of the colon wall; Stage II cancer has spread throughout the colon wall close to organs but not to lymph
nodes; Stage III – cancer has dispersed to regional lymph nodes, but not to other
normal organs; Stage IV- cancer has spread through blood and lymph circulation
to distant organs.
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Currently, various screening methods are used to diagnose and prevent
CRC, and these methods can be used differently based on the CRC stages (Burt
et al., 2013; Kuipers, Rösch, & Bretthauer, 2013). For early detection, fecal occult
blood test (FOBTs) and fecal immunochemical test (FITs) can be applied, and a
positive result from either test will lead to further screening, such as a
sigmoidoscopy and colonoscopy. Another current tool for CRC diagnosis,
involves the analysis of molecular biomarkers in a fecal samples, reflecting the
mechanisms of malignant cells (Imperiale et al., 2014).
1.1.2. Molecular Development of CRC: Vogelgram of CRC
Colorectal cancer serves as an important disease model for understanding
tumor progression and metastasis since gradual changes in phenotype are
associated with known genetic alterations (Yeatman & Chambers, 2003).
Therefore, insight into how molecular and metabolic alterations occur during the
development of the disease may uncover novel treatment strategies or aid in
CRC prevention.
In the large intestine, a monolayer of epithelial cells (i.e. stem cells,
proliferating cells, and differentiated cells) makes up the basic colonic structural
unit called the crypt. Stem and proliferating cells cover the bottom of the crypts,
while differentiated cells are found in the upper two-thirds (Riccardo Fodde,
Smits, & Clevers, 2001). CRC originates at this epithelium-layer of the mucosal
crypts. Aberrant crypt foci (ACF) are the initial sign of colorectal neoplasia. Due
to its ability to encircle other crypts, including normal and/or dysplasia cells, ACF
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promotes the formation of a polyp (Riccardo Fodde et al., 2001). The
adenomatous (dysplastic) polyp is a tumor that protrudes into the lumen of the
colon causing an aberrant inter- and intracellular structure, but most ACF or
adenomas never become cancerous (Riccardo Fodde et al., 2001). Additional
genetic alterations in oncogenes and tumor-suppressor genes are required to
develop neoplasia at the level of ACF and drive its further development into what
would be considered cancerous (Markowitz & Bertagnolli, 2009).
The Vogelgram is a model of tumor progression to CRC that provides a
better understanding of the molecular and genetic phenomenon, which occur in
CRC development. This model addresses the relationship between acquired
genetic mutations and the progression of CRC (Bellacosa, 2003). The mutations
occur in genes involved in cell proliferation, differentiation and survival that lead
to phenotypic changes needed to convert regular epithelium into an adenoma
and eventually a carcinoma (Bellacosa, 2003). The Vogelgram representation of
CRC is composed of four main genetic mutations as well as associated signaling
pathways to yield each event in CRC development and includes adenomatous
polyposis coli (APC), K-Ras, SMAD 2 and 4, and TP53 (Figure 1) (Bellacosa,
2003; R Fodde, 2002; Riccardo Fodde et al., 2001; Goel & Boland, 2012;
Markowitz & Bertagnolli, 2009; Perše & Cerar, 2014). First, the adenomatous
polyposis coli (APC) is a tumor-suppressor gene, and its mutation is the most
common event in the initiation of CRC. APC is necessary to activate the βcatenin/Wnt signaling pathway which removes extra intracellular β-catenin and
inhibit its movement into nucleus; hence, without functional APC, β-catenin/Wnt
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signaling pathway is inappropriately activated. Thus, β-catenin is not degraded
and moves to the nucleus, where it drives transcription of genes that promote the
cell cycle, such as DNA-binding proteins of the T-cell factor (TCF) family resulting
in gene transcription. The second major mutation occurs in K-Ras, which is an
oncogene that, when mutated, plays a role in the promotion by activating
mitogen-activated protein kinases (MAPK) pathway to increase cell proliferation
and decrease apoptosis. The synergetic action between abnormal APC and KRas is required to form large adenomas in CRC. SMAD 2 and 4 are pivotal
tumor-suppressor genes belonging to the growth-suppressing transforming
growth factor β (TGFβ) pathways, which results in slowing cell growth. Therefore,
mutations in these two genes play a role in the malignant transformation and
expansion of CRC. Lastly, TP53 is another critical tumor-suppressor gene in
CRC development. Inactivation of p53 leads to the loss of checkpoint for DNA
damage during the cell cycle after G phase, increasing proliferation and reducing
apoptosis and promoting malignant tumorigenesis. The most important thing to
understand about the development and progression of CRC is that it is not a
mutation in any single gene, but a combination of all of them that drives the
disease.
1.1.3. Risk Factors of CRC
The risk factors of CRC include demographic factors (age and gender),
medical conditions (family history, individual history with inflammatory bowel
disease (IBD) and metabolic diseases), lifestyle-related factors (physical activity,
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smoking and alcohol consumption) and dietary factors (Figure 2). Behavioral and
environmental modification in lifestyle-related factors such as diet has been
suggested to influence CRC incidence.
1.1.3.1. Age
According to the National Cancer Institute (NCI), incidence of CRC
increases after the age of 40 (45-54 years: 12.0%) as compared to those under
40 years old (20-24 years: 1.1%, 35-44 years: 3.8%). The likelihood of CRC
occurrence rises aggressively after the age of 50 (55-84 years: 71.1%, +84
years: 12.1%) (Horner et al., 2009). Even though the age of 50+ is an apparent
risk factor for CRC, current incidence and mortality has been decreasing in
recent years in these populations due to the early detection by routine
colonoscopy (Zauber et al., 2012). This trend holds true for other countries that
have adopted colonoscopy as a primary screening tool (Kaminski et al., 2010;
Patel & De, 2016).
Conversely, an increasing trend for CRC is being observed in the younger
population (20-49 years) (Ahnen et al., 2014; O'Connell, Maggard, Liu, & Etzioni,
2003). The incidence of CRC has been rising, and becoming one of the most
commonly diagnosed cancers in this age group (Fairley et al., 2006). This
upward pattern among younger generation may be due to the fact that they are
not generally recommended for screenings of CRC despite their high risk from
consuming a Westernized-diet (Patel & De, 2016; Yusof, Isa, & Shah, 2012).
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1.1.3.2. Gender
The impact of gender on CRC incidence and mortality has not been
clearly established. However, considering gender as a risk factor along with age,
excess body weight and obesity, there have been higher positive associations
with males in CRC incidence compared to females. Many studies have reported
that men have higher rates of CRC incidence and mortality (age-adjusted)
compared to women (Brenner, Hoffmeister, Arndt, & Haug, 2007; Brenner,
Hoffmeister, & Haug, 2008; Matanoski, Tao, Almon, Adade, & Davies‐Cole,
2006). In addition, the correlation between gender (age-adjusted) and advanced
neoplasia in the colon presents that men have a greater risk for advanced
colorectal neoplasia across all age groups than women (Nguyen, Bent, Chen, &
Terdiman, 2009). Epidemiological studies also report that the risk of CRC in
overweight or population with high body mass index (BMI) was significantly
higher in males compared to females (Brändstedt et al., 2012; Johnson et al.,
2013). The reason for the gender differences is still unclear, but the differences in
genetic background, hormones and fat distribution between male and female
have been suggested as rationales for gender-dependent differences (E
Giovannucci, 2002; McMichael & Potter, 1980; Press et al., 2008). In our studies,
HCT116 colorectal cancer cells represent an in vitro model that is routinely used.
These cells were derived from a 53-old male with a colorectal carcinoma.
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1.1.3.3. Family history
Approximately 20% of CRC cases come from the patients who have a
previous family history of this disease (Fund & Research, 2007; Haggar &
Boushey, 2009). This signifies the important genetic component associated with
CRC development. The susceptibility of CRC is increased up to 8 times in a firstdegree relative (i.e. parents, siblings, or offspring) (Haggar & Boushey, 2009;
Johns & Houlston, 2001; Johnson et al., 2013). Moreover, sibling risks are higher
than parent-offspring risks (Carstensen, Soll‐Johanning, Villadsen, Sø ndergaard,
& Lynge, 1996; Maire et al., 1984). Since early onset of CRC is mainly derived
from genetic alterations, the reasonable explanation for this strong correlation
between family history and CRC can be attributed to gene inheritance patterns
(Haggar & Boushey, 2009). In conjunction with genetic inheritance, communal
environments among family members also contributes to CRC (Slattery, 2000).
1.3.3.4. Individual History: Inflammatory Bowel Disease
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and
Crohn’s disease, is considered as a predisposing risk factor for CRC (Haggar &
Boushey, 2009). UC is a chronic disease characterized by inflammation and
colonic/rectal ulcers and Crohn’s disease is also associated with inflammations;
however, it can occur in any part of the gastrointestinal tract (GI) (NDDIC, 2013;
NIDDK, 2014). The overall risk of developing CRC in IBD patients relies on the
duration, age of onset, and the severity of the disease (Haggar & Boushey, 2009;
Johnson et al., 2013; Mellemkjæ r et al., 2000). Therefore, patients who are
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diagnosed with IBD are recommended to have regular CRC screenings (Haggar
& Boushey, 2009; Munkholm, 2003). For example, an early finding of IBD with
colonoscopy screening reduces CRC incidence (Eaden, Abrams, Ekbom,
Jackson, & Mayberry, 2000). In addition, treatment with 5-aminosalicylic acid (5ASA) decreases CRC incidence among IBD patients (Munkholm, 2003). Thus,
early detection and treatment of IBD can reduce its progression to CRC. It is
important to recognize that IBD does not cause CRC (i.e. not an initiator), but
rather is a promotor becoming the chronic through evaluated inflammatory
environment.
1.3.3.5. Metabolic Disease: Obesity and Diabetes
Obesity is a critical risk factor that increases the prevalence of other
metabolic diseases such as type II diabetes, hypertension and cardiovascular
disease (Eckel, Grundy, & Zimmet, 2005). In addition, there is ample evidence
that indicates that obesity is strongly correlated with the pathology of certain
cancers, and a risk factor for colon cancer (Calle & Kaaks, 2004). According to
epidemiological studies, a greater body mass index (BMI) and waist
circumference (WC) are positively linked with CRC (Ma et al., 2013; Patel & De,
2016). For instance, individuals who have a BMI less than 25 (BMI ≤ 25kg/m 2)
have a lower likelihood of CRC development compared to those with BMI greater
than 30 (BMI ≥ 30kg/m2) (Huxley et al., 2009). Although the role of obesity in
CRC incidence is not fully understood, abnormal metabolic changes including
insulin resistance, leptin resistance and chronic inflammation have been
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identified as underlying factors that promote the positive association between
obesity and CRC (Ma et al., 2013).
Along with obesity, diabetes is a metabolic disease that has been
correlated with CRC development (Flood, Strayer, Schairer, & Schatzkin, 2010;
Huxley et al., 2009). For example, people with diabetes have a 19% higher risk of
developing CRC compared to non-diabetics (He et al., 2010). Although the
mechanistic link between diabetes and CRC is unclear, hyperinsulinemia is
considered a direct causal factor due to the role insulin and insulin growth factor1 (IGF-1) have in tumor cell proliferation (Deng, Gui, Zhao, Wang, & Shen, 2012;
Edward Giovannucci et al., 2010). It is difficult to establish the separate
contributions from obesity and diabetes as risk factors for CRC due to their direct
influence on each other.
1.3.3.6. Lifestyle-related Factors: Physical activity, Smoking and Alcohol
Consumption
Lifestyle-related factors that impact the development of CRC include
physical activity, smoking and alcohol consumption (Haggar & Boushey, 2009).
Since these factors are modifiable, any knowledge toward how each contributes
in CRC development is pivotal in prevention.
First, participating in physical activity reduces the likelihood of developing
CRC (Haggar & Boushey, 2009; Johnson et al., 2013). When participating in
regular physical activity, the risk of CRC is decreased by 24% (Wolin, Yan,
Colditz, & Lee, 2009). Several physiological mechanisms on how regular physical
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activity attenuates CRC incidence have been suggested, but are still not clearly
understood (Haggar & Boushey, 2009; Harriss et al., 2009; Wu, Paganini-Hill,
Ross, & Henderson, 1987). These mechanisms include improvement in body
weight or BMI, improvement in insulin sensitivity, elevation of metabolic rate
(includes increase in metabolic efficiency) and enhanced GI tract motility.
Moreover, the frequency and intensity of physical activity to prevent CRC
development is important (Haggar & Boushey, 2009). For example, the American
Cancer Society (ACS) suggests at least 150 min of physical activity per week in
order to reduce CRC (Grimmett, Simon, Lawson, & Wardle, 2015; Kushi et al.,
2012).
Smoking has been known as the primary risk factor for lung cancer, but
many studies also established a positive association between smoking and CRC
(Haggar & Boushey, 2009; Johnson et al., 2013; Patel & De, 2016). A metaanalysis reports that 20% of smokers have an elevated risk for CRC in
comparison with people who have never smoked (Tsoi et al., 2009). In addition,
the frequency of smoking plays a role in CRC risk. Johnson et al. (2013) found
an 11% increased risk of CRC from smokers with 17 cigarettes/month and 21%
increased risk in CRC from smokers with 34 cigarettes/month compared to nonsmokers (Johnson et al., 2013). The effects of smoking on CRC may be
explained by the carcinogens produced from cigarettes which accelerate tumor
formation and growth (Botteri, Iodice, Raimondi, Maisonneuve, & Lowenfels,
2008).
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Like smoking, alcohol consumption is associated with an increased
incidence of CRC. The frequency and quantity of alcohol consumption are also
significantly related to CRC development (Haggar & Boushey, 2009; Wu et al.,
1987). For example, the relative risk (RR) for CRC when consuming 10, 50, and
100 g/day alcohol consumption was 1.07, 1.38 and 1.82, respectively (Moskal,
Norat, Ferrari, & Riboli, 2007). Heavy alcohol consumption may result in
carcinogen formation in colon, failure in DNA repair and inefficient absorption of
nutrients in the colon, making cells vulnerable to tumor formation and CRC (Fund
& Research, 2007; Haggar & Boushey, 2009).
In summary, regular physical activity, smoking cessation, and limiting
alcohol consumption are strongly suggested to prevent CRC development and
reduce mortality.
1.3.3.7. Dietary Factors
Dietary factors strongly impact CRC development because dietary factors
can act as pro- and/or anti- cancer factors at any point in the multiple stages of
CRC pathology (Vargas & Thompson, 2012). Thus, dietary factors can be utilized
successfully to decrease the CRC incidence and progression (Haggar &
Boushey, 2009; Vargas & Thompson, 2012).
Convincing dietary factors include red and processed meat, dietary fibers
and whole grains. High consumption of red and processed meat is a high risk
factor for CRC (Chan et al., 2011; Edward Giovannucci et al., 1994). Chan et al.
(2001) observed that the risk of CRC elevated by 29% for every 100 g/day of red
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meat intake and 21% for every 50 g/day of processed meat consumption (Chan
et al., 2011). In addition to the amounts of consumption, the frequency of red and
processed meat intake also increase the risk of CRC development by 13% and
9% for five servings per week respectively (Johnson et al., 2013). Moreover, the
cooking temperature and time of red and processed meat is also partially
involved in the risk of CRC incidence (de Verdier, Hagman, Peters, Steineck, &
Ö vervik, 1991). The potential mechanisms involved in CRC development have
been found to involve the natural (heme) and artificial (nitrite-preserve)
containing DNA-damaging N-nitroso compounds that occur in both red meat and
processed meat (Babbs, 1990; Cross, Pollock, & Bingham, 2003; Santarelli,
Pierre, & Corpet, 2008). The N-nitroso compounds have a direct cytotoxic and
genotoxic impacts on the epithelium layer of colon and increase lipid peroxidation
to promote colorectal tumorigenesis (Bastide et al., 2015; Bastide, Pierre, &
Corpet, 2011).
There is ample evidence that demonstrates low consumption of dietary
fiber increases the risk of CRC (Aune, Chan, et al., 2011; Park et al., 2005). For
instance, low fiber intake (<10 g/day) increases the risk of CRC by 18%
compared to higher intake (10-15 g/day) (Park et al., 2005). In addition, in
reference to dietary fiber components, whole grains have a negative association
with CRC incidence (Aune, Chan, et al., 2011; Jacobs Jr, Marquart, Slavin, &
Kushi, 1998; Schatzkin et al., 2007). A meta-analysis using case-control
publications found that high consumption of whole grains reduced the risk of
CRC incidence by 20% (Jacobs Jr et al., 1998). The next section (1.2 The role of

16

dietary fibers in CRC) will discuss the relationship between dietary fibers and
CRC in more detail, which will include the epidemiological findings and its
underlying mechanisms that maybe involved in CRC prevention.
Limited, but suggestive dietary factors that impact CRC development
include high-fat diets and low intake of fruits and vegetables. Various studies
report that consuming a diet high in overall/total fat, saturated fat and animal fat
increase CRC development (T. T. Fung et al., 2010; Graham, Dayal, Swanson,
Mittelman, & Wilkinson, 1978). However, in other studies, there was no
association between fat intake and CRC (Alexander, Cushing, Lowe, Sceurman,
& Roberts, 2009; Edward Giovannucci et al., 1994). Importantly, because of the
inconsistent findings in epidemiological studies, it is difficult to define the
contribution of dietary fat content toward CRC incidence. However, a high intake
of fat increases the total energy intake and the likelihood of obesity that is
significantly associated with CRC (GRAHAM et al., 1988; Ma et al., 2013). It has
been demonstrated that saturated fatty acids increase inflammation, change bile
acid metabolism, and colon environments, which leads to an elevated risk for
CRC development (Mathias & Dupont, 1979; Van Eldere, Celis, De Pauw,
Lesaffre, & Eyssen, 1996). Therefore, lower consumption of saturated fat and
animal fat is suggested to prevent CRC incidence.
Overall epidemiological studies regarding the relationship between fruit
and vegetable intake and CRC incidence suggests there is an inverse correlation
(Johnson et al., 2013; Patel & De, 2016). High intake of fruits and vegetables
decreased the risk of CRC (Aune, Lau, et al., 2011). These findings were
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controversial since other studies found no association between fruits and
vegetables intake and CRC (van Duijnhoven et al., 2009). Although the beneficial
effects of fruits and vegetables consumption on CRC incidence are still not
clearly established, many experimental studies found that bioactive compounds
and antioxidants in fruits and vegetables have anti-inflammatory, anti-cancer and
tumor-suppressive effects (Liu, 2003; Steinmetz & Potter, 1996; Vanamala et al.,
2006). Therefore, the intake of fruits and vegetables is recommended to reduce
the incidence and mortality of CRC.
In conclusion, dietary factors play an important role in CRC incidence. In
addition, because dietary factors can be manipulated, it is important to implement
public awareness and intervention. Therefore, based on the findings from the
epidemiological and clinical studies, Figure 3 describes dietary recommendations
in order to prevent CRC incidence.

1.2 Role of Dietary Fiber in CRC
Although advancements in technology related to detecting CRC have
lowered CRC incidence, it is still the third deadliest cancer in the United States
(Kahi, Imperiale, Juliar, & Rex, 2009; Siegel et al., 2016). As described in section
1, dietary factors are important in decreasing CRC incidence, slowing
progression and aiding in prevention (Vargas & Thompson, 2012). Although
controversial, the importance of dietary fiber (DF) in CRC incidence has been
established through many epidemiological studies (Baena & Salinas, 2015; Park
et al., 2005; Romaneiro & Parekh, 2012; Trock, Lanza, & Greenwald, 1990).
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However, special attention has been devoted to the relationship between CRC,
DF, and the functions of the gut microbiota (Davis & Milner, 2009; Sears &
Garrett, 2014; Zackular et al., 2013). For example, the metabolism of DF through
the gut microbiota is highly associated with colonic health, the development of
CRC, and the general health of an individual (Cani & Delzenne, 2009; Sekirov,
Russell, Antunes, & Finlay, 2010). Section 2 will present a general introduction of
DFs as well as a summary of previous studies regarding the role of DFs in CRC
incidence. In addition, the general information for gut microbiota and its roles in
CRC will be described.
1.2.1. General Introduction: Definition, Classification and Physiological
roles of DF
It is difficult to describe a single, simple definition of DF because there is
no standard definition and it varies between organizations (Table 1). According to
current definitions, the term ‘dietary fiber’ compromises a broad spectrum of
information on DF from the sources (plants and animal substances), chemical
properties, and physiological effects to origin (natural and synthesized). These
diverse definitions of DF can be problematic due to their inability to provide
unified guidelines for DF in food labeling, references of nutrients values, and
health claims (Cummings, Mann, Nishida, & Vorster, 2009). In 2008, the Codex
Committee on Nutrition and Foods for Special Dietary Uses (CCNFSDU)
addresses ‘an agreed definition’ of DFs in order to impose a more clear standard
(Table1). (Alimentarius, 2008).
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Dietary fiber come from natural and/or artificial sources. As listed in Table
2, naturally-occurring DF includes indigestible-polysaccharides (non-starch
polysaccharides, cellulose, hemicellulose, pectin, β-glucans, gums and
mucilages), resistant oligosaccharides (inulin and fructo-oligosaccharides),
analogous carbohydrates (resistant -starch and -dextrin), lignin, constituents of
plants (suberin, waxes and cutin), algal materials, and animal substances (chitin,
chitosan, collagen and chondroitin). Artificial DF include resistant
oligosaccharides (fructo-oligosaccharides and galacto-oligosaccaharides) and
analogous carbohydrates (resistant -starch and -dextrin, modified cellulose and
polydextrose) (Gropper & Smith, 2012; Mudgil & Barak, 2013; Tungland & Meyer,
2002). The general classifications of DF rely on their origins and/or
physicochemical properties (Table 3) (Blackwood, Salter, Dettmar, & Chaplin,
2000; Joanne Slavin, 2013; J. L. Slavin & Lloyd, 2012; Tungland & Meyer, 2002).
However, some studies classify DF based on their physiological effects and their
physicochemical properties (J. L. Slavin & Lloyd, 2012). Physicochemical
properties of DF include solubility, viscosity and fermentability, and each of these
properties is commonly associated with each other (Gropper & Smith, 2012;
Raninen, Lappi, Mykkänen, & Poutanen, 2011; Tungland & Meyer, 2002). For
example, soluble fiber is more likely to have high viscosity and fermentability;
whereas insoluble fiber has relatively low viscosity and poor and/or partial
fermentability (Table 3).
Major physiological effects of DF can be described as: improvements of
blood lipid and glucose levels, laxation, overall improvement of colonic health
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and decreased CRC development (Anderson et al., 2009; Blackwood et al.,
2000; Gropper & Smith, 2012; Kendall, Esfahani, & Jenkins, 2010; Mudgil &
Barak, 2013; Raninen et al., 2011; J. L. Slavin & Lloyd, 2012; Tungland & Meyer,
2002). Figure 4 shows the physiological effects of DF and their underlying
mechanisms. In addition, many studies demonstrate that DF have a beneficial
impact on cardiovascular disease, diabetes, and body weight, and appetite
(Anderson et al., 2009; Kristensen & Jensen, 2011; Joanne Slavin, 2013; J. L.
Slavin, 2005).
According to the Institute of Medicine (IOM), an adequate intake (AI) of DF
is 14 g of fiber/1000 kcal from age one and above (J. L. Slavin & Lloyd, 2012;
Stipanuk & Caudill, 2013). The conversion of AI is based on median energy
intake and is equal to 25 g/day for women and 38 g/day for men ages 19- 50
years (Stipanuk & Caudill, 2013). However, the current average DF consumption
of Americans is ~ 15 g per day, which fails to meet the AI levels (JL Slavin,
2008). Therefore, food choices is pivotal in order to meet the recommended
levels of DF and reduce the risk of chronic disease such CRC. Foods rich in fiber
that help meet the AI levels include whole grains, legumes, fruits and vegetables
(Stipanuk & Caudill, 2013).
1.2.2. A Summary of Previous Studies: The Roles of DF in CRC
Although DF have diverse physiological roles, there has been a large
focused on the effects of DF on general colonic health, which may aid in the
decrease in CRC incidence (Figure 4). In the last decade, epidemiological
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studies have indicated that high intakes of DF prevent CRC, but some studies
have suggested that there is no and/or weak association between DF intake and
CRC risk (Anderson, Smith, & Gustafson, 1994; Baena & Salinas, 2015; Howe et
al., 1992; Park et al., 2005). Moreover, the correlation between the intake of DF
and CRC depends on which variables are applied such as age and/or sources of
DF. Table 4 summarizes these epidemiological studies regarding the intake of
DF and its impact on CRC incidence (Aune, Chan, et al., 2011; Bingham et al.,
2003; Dahm et al., 2010; Fuchs et al., 1999; Howe et al., 1992; Mai et al., 2003;
Michels et al., 2000; Park et al., 2005; Terry et al., 2001; Trock et al., 1990).
Based on evidence regarding an inverse relationship between DF and CRC,
studies are categorized as protective effects’; ‘no and/or weak association’; or
‘changeable depending on variables’.
Discordant associations from previous publications may be due to several
reasons. For example, limitations of epidemiological studies include: potential
bias and confounders, such as the measurement of DF consumption; interactions
with other nutrients; and potential influences from lifestyle factors such as
smoking, physical activity, and body weight (Baron, 2005). Other conflicting
results may be due to study design, such as population size and the follow-up
period (Baron, 2005; Lawlor & Ness, 2003; Romaneiro & Parekh, 2012). In
addition, multiple definitions and classification of DF across studies complicate
the findings (Potter, 1990). Overall, the differences in DF sources in these
studies make it difficult to generate consistent associations between DF and
CRC risk (Potter, 1990; Romaneiro & Parekh, 2012; Terry et al., 2001). Other
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variables include genetic background and the community of gut microbiota, which
may contribute to conflicting findings from the epidemiological studies (Lozupone,
Stombaugh, Gordon, Jansson, & Knight, 2012). For example, a change of gut
microbiota structure by diet is associated with CRC development (Ahn et al.,
2013; Sobhani et al., 2011). Moreover, the differences in gut microbiota between
healthy and CRC subjects indicate the important roles of gut microbiota in CRC
risk (Clemente, Ursell, Parfrey, & Knight, 2012). Therefore, failure to consider gut
microbiota differences in the subjects can cause discordant results.
1.2.3. Gut Microbiota: Definition, Physiological Functions and Importance
Microbiota, microflora and normal flora are all terms to describe the
gathering of microorganisms (bacteria, archaea, viruses, and unicellular
eukaryotes) living in the human body (Sekirov et al., 2010). The majority of
microbiota is composed of bacteria in the human body, and most of them
colonize in the gastrointestinal tract (GI), especially the colon. These organisms
have been defined as gut microbiota. Through the Human Microbiome Project
(National Institutes of Health, 2008), the composition and functions of gut
microbiota have been identified and characterized (Gill et al., 2006; Peterson et
al., 2009). Approximately 1000 different species of bacteria exist in the colon,
and these bacteria produce saccharolytic enzymes that metabolize undigested
nutrients (Joanne Slavin, 2013; Tungland & Meyer, 2002). DF such as pectin,
guar gum, fructo-oligomers, and resistant starch are the primary substrates for
this fermentative metabolism by colonic bacteria (Blaut, 2002; Tungland & Meyer,
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2002). These are fermented into various end-products such as short chain fatty
acids (SCFAs; acetate, propionate and butyrate) and gases (H2, CO2 and CH4)
which impact various physiological mechanisms to maintain host health (Holmes,
Li, Athanasiou, Ashrafian, & Nicholson, 2011; Kinross, Darzi, & Nicholson, 2011;
Macfarlane & Macfarlane, 2012). For example, the metabolites produced by gut
microbiota help maintain epithelial homeostasis, regulate lipid metabolism,
promote nutrient digestion and absorption and mediate immune-cell development
(Holmes et al., 2011). Figure 5 describes the effects of bacterial-derived
metabolites and their underlying mechanisms (Blackwood et al., 2000;
Macfarlane & Macfarlane, 2012; Sekirov et al., 2010; Joanne Slavin, 2013).
Current publications support the notion that SCFAs orchestrate the central
effects of gut microbiota for host and colonic health. Acetate (C2), propionate
(C3) and butyrate (C4) are the major SCFAs produced by bacterial-fermentation
in the colon with concentrations ranging from 60 to 150 mM in humans
(Cummings, Pomare, Branch, Naylor, & Macfarlane, 1987; Nordgaard &
Mortensen, 1994). SCFAs are involved in both host energy metabolism and
colonic homeostasis as a major energy source. Acetate and propionate are
absorbed and transported to the liver and other tissues for metabolism to ATP
(Blaut, 2002). Butyrate is directly absorbed by colonic epithelial cells and utilized
as the primary energy source for colonocytes (Donohoe et al., 2011; Hague,
Singh, & Paraskeva, 1997; Hamer et al., 2008). Additionally, colonic bacteria can
utilize their self-produced SCFAs as energy sources. Therefore, SCFAs
produced by gut microbiota are associated with the structural and homeostatic
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balance that is an important component toward achieving a healthy colonic
environments (Topping & Clifton, 2001). Since SCFAs are weak acids, they lower
intestinal pH resulting in a decrease risk of CRC incidence (Hamer et al., 2008;
Tungland & Meyer, 2002). Lower intestinal pH leads to diminished
carcinogenesis via altered bile acid metabolism, peptide degradation, and
formation of toxic compounds in the colon.
Extensive research has been conducted to identify the contributions of
specific colonic microbe/microbial groups or microbial-derived molecules to host
health and diseases (Kinross et al., 2011; Sekirov et al., 2010). Kinross et al.
(2011) mentioned that gut microbiota have been directly associated with multiple
diseases including circulatory disease, obesity, IBDs and CRC. Therefore, an
interruption of colonic- and gut microbial-homeostasis is significantly related to
the development of those diseases (Kinross et al., 2011). Factors that change
gut microbiota and its resulting metabolites are the host’s physiological status
(age, stress, health condition and genotype), diet (high-fat and DF) and
environmental conditions, such as antibiotic therapy (Figure 6) (Blackwood et al.,
2000; Joanne Slavin, 2013). Of these factors, the role of diet is the most critical
since diet directly influences the composition of gut microbiota and the production
of microbial-derived metabolites (Scott, Gratz, Sheridan, Flint, & Duncan, 2013).
A high-fat diet decreases total gut microbial levels and increases Gram-negative
bacteria (Holmes et al., 2011). In addition, dietary fructose-oligomer and -polymer
beneficially alter the bacterial compositions by increasing Bifidobacteria, whereas
resistant starch prompts the growth of anaerobic Clostridia (Jaskari et al., 1998;

25

May, Mackie, Fahey, Cremin, & Garleb, 1994). Distinct DFs have different effects
on the composition and quantity of bacterial-derived metabolites. For instance,
guar gum generates the highest levels of total SCFAs compared to other DF,
while ispaghula produces higher level of butyrate rather than other SCFAs
(Blackwood et al., 2000).
In conclusion, gut microbial homeostasis is a significant factor in
maintaining a healthy colonic environment, which in turn decreases the risk of
CRC. Diet plays a critical role in helping determine gut microbiota and
maintaining this colonic homeostasis.
1.2.4. Gut Microbiota and CRC
Accumulating findings emphasize the involvement of gut microbiota in
CRC development through physiological mechanisms resulting from microbialderived metabolites and from an alterations of metabolic composition (Holmes et
al., 2011; Kinross et al., 2011).
First, the structure of gut microbiota contributes to the etiology of CRC
(Hagland & Sø reide, 2015; O'Keefe, 2008). For example, alterations in the
diversity and number of gut microbiota provide possible mechanisms to develop
CRC (Figure 6). These mechanisms include the production of bacterial-derived
carcinogenic metabolites, increases in disadvantageous bacteria (ex.
Streptococcus spp., Escherichia Coli, Fusobacterium nucleatum, Clostridium and
Bacteroides) and decreases in beneficial species (ex. Bactobacillus) (O'Keefe,
2008; Sobhani et al., 2011). According to Louis et al. (2014), particular
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pathogenic bacteria (ex. Clostridium difficile, Fusobacterium spp., and
Campylobacter spp.) promote CRC development via pro-inflammatory
interactions with mucosal tissues, such as reactive oxygen species (ROS)
production and subsequent DNA damage (Louis, Hold, & Flint, 2014). In addition,
elevation of sulfur-reducing bacteria (Desulfovibrio Vulgaris) accompanied by
high meat consumption yields carcinogenic compounds such as hydrogen
sulfide, which causes DNA damage, mucosal inflammation, and cell death
(Bultman, 2014a; O'Keefe, 2008). Hence, understanding the functions of
individual bacteria and the potential carcinogenic metabolites produced by these
bacteria during physiological conditions is pivotal in preventing CRC (Sears &
Garrett, 2014; Sobhani et al., 2011).
Next, as mentioned in the previous section, gut microbiota plays a
significant role in colonic- and microbial- homeostasis through the production of
metabolites that reduce CRC development (Figure 5). More than any other
bacterial-derived metabolites, butyrate has been highlighted as a tumorsuppressive molecule due to its specialized biochemical role (Davie, 2003;
Havenaar, 2011; Tong, Yin, & Giardina, 2004). By acting as a histone
deacetylase inhibitor (HDACi), butyrate suppresses cell proliferation and
increases apoptosis in CRC in vivo and in vitro (Donohoe, Collins, et al., 2012;
Hague et al., 1993; Holmes et al., 2011; Macfarlane & Macfarlane, 2012).
Interestingly, the overall reduction of butyrate-producing bacteria (ex. Roseburia,
Fecalibacterium prausnitzii, and Eubacterium rectale) has been observed when
comparing the fecal and tissue samples from healthy individuals and CRC
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patients (Balamurugan, Rajendiran, George, Samuel, & Ramakrishna, 2008;
Bultman, 2014a; Chen et al., 2013; Wang et al., 2012). In the next section (1.3
Butyrate), a more comprehensive review on butyrate, its functions, and its
metabolism in both normal and CRC conditions will be addressed.
A diet intervention, particularly including DF and/or pre/probiotics,
improves the community of gut microbiota and SCFAs production leading to the
amelioration of tumor size and numbers in CRC progression (Chen et al., 2013;
Davis & Milner, 2009; Zackular et al., 2013). Prebiotics and probiotics block the
detrimental effects of gut microbiota and the potential carcinogenic mechanisms
by introducing beneficial living bacteria strains (probiotics) or substrates
(prebiotics) (Bultman, 2014a; Geier, Butler, & Howarth, 2006). In conclusion,
targeting certain pathogenic bacteria and improvement of bacterial composition
through the probiotic or prebiotics represents a promising preventative strategy
toward CRC.

1.3 Butyrate
The gut microbiota produces diverse metabolites, resulting from the
fermentation of DFs. Of these metabolites, special attention has focused on
SCFAs due to their contributions in the maintenance of microbiota structure and
colonic health (Figure 5). In particular, butyrate functions as the primary energy
source for colonic epithelial cells and acts as an HDACi to regulate cell
proliferation, apoptosis and differentiation (Davis & Milner, 2009; Havenaar,
2011). However, butyrate has the ability to impose contrasting effects on
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cancerous colonocytes compared to normal colonocytes. This has been referred
to as the ‘butyrate paradox’ (Bultman, 2014a; Leonel & Alvarez-Leite, 2012).
Section 3 will provide more information regarding the origination of butyrate, its
functions and metabolism, and explanations for the butyrate paradox.
1.3.1. Butyrate: Synthesis and Functions
In the colon, several bacteria species are responsible for synthesizing
butyrate and are divided into two main groups according to enzymes in the last
steps of their butyrate production pathway (Flint, Duncan, Scott, & Louis, 2015).
Butyrate is produced by bacteria employing either butyryl-CoA: acetate-CoA
transferases or less frequently, phosphotransbutyrylase and butyrate kinase as
final enzymes of the pathway (Figure 7) (Flint, Duncan, Scott, & Louis, 2007;
Louis et al., 2014). Eubacterium rectale, Roseburia spp., Coprococcus catus,
Anaerostipes spp., Eubacterium hallii and Faecalibacterium prausnitizii are
bacterial species that produce butyrate via the CoA-transferase pathway.
Coprococcus eutactus and Coprococcus comes produce butyrate via the
butyrate kinase pathway. In addition to these two main pathways, butyrate can
be generated from other metabolites, this is sometimes referred to as crossfeeding. For instance, Eubacterium hallii and Anaerostipes caccae can convert
acetate and lactate into butyrate (Pryde, Duncan, Hold, Stewart, & Flint, 2002).
The production of butyrate is affected by several factors, including an
individual’s difference in gut microbiota, intestinal pH, sources of DF, and other
bacterial-derived metabolites and environmental factors (biotic therapy) (Flint et
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al., 2015; Guilloteau et al., 2010; Pryde et al., 2002). Appropriate intestinal pH is
pivotal to maintain butyrate-producing bacteria and butyrate levels in the colon.
For example, an in vitro fermentation study found that the population of butyrateproducing bacteria and the butyrate level was higher at pH 5.5, suggesting that
lower intestinal pH helps to maintain a beneficial environment for butyrateproducing bacteria (Walker, Duncan, Leitch, Child, & Flint, 2005). Although most
fermentable DF play a role in SCFAs productions, resistant starches and fructooligosaccharides are considered the most effective butyrogenic DF (Guilloteau et
al., 2010; Topping & Clifton, 2001). Moreover, other metabolites such as acetate
and lactate are critical in butyrate’s synthesis due to microbial community
interaction and cross-feeding (Pryde et al., 2002).
The approximate butyrate concentration in the human colon ranges from
10 to 30 mM (total SCFAs concentration is 60-150 mM). The majority of the
butyrate (95%) is rapidly absorbed into and utilized by colonic epithelial cells
resulting in undetectable butyrate levels in portal blood (Louis et al., 2014; Pryde
et al., 2002; Rémésy, Demigne, & Morand, 1992). Butyrate is mainly transported
into colonocytes via monocarboxylate transport protein 1 (MCT1) (M Astbury & M
Corfe, 2012). Once transported into the cell, butyrate undergoes mitochondrial βoxidation to produce acetyl-CoA, which then enters the TCA cycle and is used for
ATP production (Hagland & Sø reide, 2015). β-oxidation of butyrate is modulated
by several enzymes including short-chain acyl-CoA dehydrogenase (SCAD),
enoyl-CoA hydratase, and short-chain hydroxyacyl-CoA dehydrogenase
(SCHAD) (M Astbury & M Corfe, 2012). Of these enzymes, SCAD plays a
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significant role in butyrate metabolism; hence, SCAD deficiency increases
butyrate excretion and decreases catabolism up to 60% (Bhala et al., 1995; M
Astbury & M Corfe, 2012). In addition, the deletion and/or mutation of SCAD
results in inefficient metabolism of butyrate as an energy source (Augenlicht et
al., 1999). Donohoe et al. (2011) observed that colonocytes of germfree mice
(lacking bacterial-derived butyrate production) have lower expression of key
enzymes necessary for the TCA cycle (Donohoe et al., 2011). Interestingly, the
addition of butyrate allows germfree mice colonocytes to recover their defects in
mitochondrial respiration and inhibit their autophagy. Moreover, this rescue is
due to butyrate’s role as an energy substrate for colonocytes rather than as an
HDACi (Donohoe et al., 2011). Later it was reported that the proximal colon of
germfree mice showed lower ATP levels when compared to other tissues
(Donohoe, Wali, Brylawski, & Bultman, 2012). However, the addition of a
butyrate-fortified diets partially rescued the slowed cell cycle and stimulated
oxidative metabolism in germfree colonocytes, thus suggesting that butyrate was
a major factor in these two processes (Donohoe, Wali, et al., 2012). This
evidence also illustrates butyrate’s primary role as an energetic substrate for
colonocytes. Butyrate is also a crucial substrate for lipogenesis through the
mitochondrial β-oxidation pathway and eventual conversion to cytosolic acetylCoA (Rémésy et al., 1992). Specifically, butyrate-derived acetyl-CoA in the
mitochondria in combination with oxaloacetate (OAA) is used to generate citrate
in the initial step of the TCA cycle. Citrate is then exported into the cytosol, where
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it is broken back down into acetyl-CoA and OAA (Bultman, 2014b). The acetylCoA provides the initial backbone used in lipogenesis.
Another major function of butyrate is its role as an HDACi which regulates
epigenetic modifications by increasing histone acetylation (Havenaar, 2011;
Macfarlane & Macfarlane, 2012). HDACs inhibition relaxes the chromatin
wrapped around histones, making DNA more accessible to transcription factors
and eliciting a subsequent change in gene expression (Encarnacao, Abrantes,
Pires, & Botelho, 2015). Butyrate has been deemed as the strongest HDACi
among bacterial-derived SCFAs, which allows it to effectively reduce cell
proliferation and regulate the expression of specific genes such as cyclindependent kinase, p21 and pro-apoptotic proteins, BAX and Fas (Bultman,
2014b; Davie, 2003). Most HDACs, except class III HDAC and class II HDAC 6
and 10, are suppressed by butyrate (Davie, 2003). As an HDACi, butyrate also
protects against intestinal inflammation via suppression of NF-γB activation,
inhibition of interferon-γ production and/or signaling, and upregulation of PPAR-γ,
suppression of oxidative stress via reduction of H2O2-induced DNA damage,
enhanced antioxidant glutathione activity and increase catalase and glutathioneS-transferase (Canani, Di Costanzo, & Leone, 2012; Hamer et al., 2008; Jacobs,
Gaudier, Duynhoven, & Vaughan, 2009; Leonel & Alvarez-Leite, 2012; Scharlau
et al., 2009). Butyrate can also exert beneficial effects in the intestinal barrier
(Plöger et al., 2012). Due to the multiple effects of butyrate, it has received
widespread attention as a general anti-CRC molecule.
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Recent advances indicates that butyrate’s role in histone acetylation is
more complicated than previously described (Bultman, 2014b; Donohoe, Curry, &
Bultman, 2013). According to Donohoe et al. (2012), butyrate is involved in
histone acetylation through two distinct mechanisms, ACL-dependent and/or
ACL-independent, which relies on butyrate concentrations (Bultman, 2014b;
Donohoe, Collins, et al., 2012). This dose-base mechanism is significant with
regards to regulation of cell proliferation and/or apoptosis of colonocytes (Figure
8) (Bultman, 2014b; Donohoe, Collins, et al., 2012; Donohoe et al., 2013). For
example, an ACL-dependent mechanism is more likely to occur at relatively low
doses of butyrate (0.5 mM) where butyrate undergoes mitochondrial β-oxidation,
producing acetyl-CoA via ACL. Although cytosolic acetyl-CoA is utilized to
synthesize lipids, nuclear acetyl-CoA serves as a cofactor for histone
acetyltransferases (HATs) (Wellen et al., 2009). In the nucleus, butyrate modifies
histone acetylation, accounting for 75% of gene expression, which is mostly
related to cell proliferation (Donohoe, Collins, et al., 2012). In contrast, at high
doses (5 mM), butyrate accumulates in the nucleus and mediates histone
acetylation as a HDACi (ACL-independent mechanism). The accumulation of
butyrate at high concentrations is due to the limited oxidative metabolic ability of
these cells (1-2 mM) (Andriamihaja, Chaumontet, Tome, & Blachier, 2009). As an
HDACi, butyrate accounts for 75% gene expression (such as FAS and WNT10B)
which are associated with apoptosis (Donohoe, Collins, et al., 2012).
Butyrate is believed to exist in a gradient of higher concentration in the
upper side of the crypts and lower levels at the base of the crypts due to the
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mucous flow (Donohoe, Collins, et al., 2012; Tan et al., 2014). According to the
previous findings, the base of the crypts is composed of proliferative cells while
the upper part of the crypts is filled with apoptotic cells for luminal exfoliation
(Bultman, 2014b; Donohoe, Collins, et al., 2012; Yu, Wang, Wei, & Ni, 2012).
The recent findings indicate that butyrate’s regulation of gene expression
differences may be due to dose-dependent mechanisms (Donohoe, Collins, et
al., 2012). Therefore, butyrate may maintain colonic epithelial cells homeostasis
through these interesting mechanisms (ACL-dependent and/or ACLindependent) that regulate gene expression (Figure 8) (Bultman, 2014b;
Donohoe, Collins, et al., 2012). Overall, the relationship between the metabolic
fate of butyrate (being oxidized and/or accumulated) and its functions (i.e.
HDACi) may account for the inconsistent butyrate actions in normal versus
cancerous colonocytes (Donohoe et al., 2013; Hague et al., 1997; Leonel &
Alvarez-Leite, 2012). The next section (1.3.2. cancer cell metabolism -The
Warburg effect) will cover the metabolic characteristics of cancerous cells that
may influence butyrate’s metabolism and its functions.
The ability of butyrate to regulate biological mechanisms also comes from
interactions with G-protein-coupled receptors (GPCRs) that modulate signaling
pathways (Louis et al., 2014). Butyrate can be a ligand for GPR41, GPR43, and
GPR109A that are expressed along the entire GI tract (Guilloteau et al., 2010;
Jacobs et al., 2009; Tan et al., 2014). GPR 43 and GPR 41 are primarily
expressed in the intestinal endocrine L-cell, where it releases intestinal peptide
YY (PYY) and glucagon-like peptide 1 (GLP-1) (Kasubuchi, Hasegawa,
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Hiramatsu, Ichimura, & Kimura, 2015). PYY suppresses the appetite as an
neuroendocrine factor and GLP-1 stimulates the pancreas to secrete insulin
(Gropper & Smith, 2012; Stipanuk & Caudill, 2013). Tolhurst et al. (2012)
observed that butyrate triggers GLP-1 secretion in mixed colonic cultures in vitro
(Tolhurst et al., 2012). In addition, administration of tributyrin, a butyrate prodrug,
improves insulin resistance in obese mice (Vinolo et al., 2012). By interacting
with GPR109A, butyrate also attenuates colonic inflammation and antiinflammatory mechanisms via colonic immune cells (Kasubuchi et al., 2015).
Thus, butyrate can enhance insulin sensitivity, mediate food intake and inhibit
colonic inflammation as a ligand of GPCRs (Kasubuchi et al., 2015; Tan et al.,
2014).
As an energy substrate, epigenetic regulator and GPCR ligand, butyrate
can be involved in a variety of mechanisms related to colonic and host health
(Figure 9). However, the most highlighted role of butyrate is as an HDACi, which
is highly associated with its metabolic fate in colonocytes. Therefore, it is
important to understand butyrate’s metabolic fate in colonocytes in order to
identify its anti-cancer mechanisms against CRC.
1.3.2. Cancer Cell Metabolism -The Warburg Effect
Cancer cell metabolism is often described as involving the Warburg effect,
which is characterized by rapid glucose utilization and lactate production (also
known as aerobic glycolysis) (Warburg, 1956b). In aerobic glycolysis, most
cancer cells rapidly metabolize glucose for ATP generation (~4 ATP/mol
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glucose), rather than the more efficient pathway of oxidative phosphorylation
(OXPHOS, ~36 ATP/mol glucose) (Cairns, Harris, & Mak, 2011; Vander Heiden,
Cantley, & Thompson, 2009). In the 1950s, Otto Warburg hypothesized that
mitochondrial dysfunction lead to this metabolic phenomenon in cancer cells;
however, it has been demonstrated that most cancer cells maintain their normal
OXPHOS ability (Garber, 2004; Rossignol et al., 2004; Warburg, 1956a). It has
been suggested that the Warburg effect is the metabolic adaptation of the cancer
cells in order to obtain abundant ATP production and biosynthetic advantages
(Hsu & Sabatini, 2008; Kaelin Jr & Thompson, 2010).
Cancer cells consume high levels of energy and proliferate rapidly,
requiring sufficient amounts of ATP as well as ample cellular components such
as nucleotides, fatty acids, membrane lipids, and proteins availability for rapid
growth (Hsu & Sabatini, 2008). Although aerobic glycolysis is less efficient
regarding ATP production, the abnormal glycolytic rate of cancer cells can
counteract this low productive efficiency (Feron, 2009; Vander Heiden et al.,
2009). According to previous research, cells using aerobic glycolysis also have a
high ratio of ATP/ADP and NADH/NAD exceeds the results from OXPHOS
(DeBerardinis, Lum, Hatzivassiliou, & Thompson, 2008; Vander Heiden et al.,
2009). In addition, this fast glycolytic rate allows the cancer cells to obtain the
required building blocks needed for their rapid cellular expansions (Jones &
Thompson, 2009). The TCA cycle is known as a main bioenergetic center as well
as biosynthetic hub for the cells by supplying diverse precursors for nucleotides,
lipids and protein synthesis (DeBerardinis, Sayed, Ditsworth, & Thompson, 2008;
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Jones & Thompson, 2009). As shown in figure 10, the high rate of aerobic
glycolysis allows cancer cells to obtain biosynthetic intermediates via the TCA
cycle (DeBerardinis, Sayed, et al., 2008; Feron, 2009; Jones & Thompson,
2009). The pentose phosphate pathway generates ribose-5-phosphate for
nucleotide synthesis, and NADPH (nicotinamide adenine dinucleotide phosphate,
reduced) for nucleotides and fatty acids synthesis (Jones & Thompson, 2009;
Vander Heiden et al., 2009). In addition, cytosolic citrate is cleaved by ATPcitrate lyase (ACL) to supply acetyl-CoA, which is the lipogenic precursor for
cholesterol and fatty acids synthesis and oxaloacetate (OAA) for non-essential
amino acids (Feron, 2009; Hsu & Sabatini, 2008).
The mechanisms that permit cancer cells to achieve this metabolic
transformation are stimulated by altering signaling pathways; mutations in
oncogenes and tumor-suppressor genes; and modifying expressions of enzymes
that impact metabolic flux rate and activity (Bensinger & Christofk, 2012; Dang &
Semenza, 1999; DeBerardinis, Sayed, et al., 2008; Kim & Dang, 2006; Ward &
Thompson, 2012). These molecular and cellular alterations cause the cancer
cells to preferably use aerobic glycolysis rather than OXPHOS, resulting in an
efficient bioenergetic and biosynthetic system for rapid growth and proliferation
(Table 5) (Bensinger & Christofk, 2012; Cairns et al., 2011; DeBerardinis, Lum, et
al., 2008; DeBerardinis, Sayed, et al., 2008; Feron, 2009; Hsu & Sabatini, 2008;
Ward & Thompson, 2012). The current understanding behind metabolic
transformation of cancer cells allows more specific therapeutic approaches
against cancer (Tennant, Durán, & Gottlieb, 2010). For example, dichloroacetate
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(DCA), an inhibitor of pyruvate dehydrogenase kinase, ameliorates tumor growth
in vivo and in vitro studies (Michelakis, Webster, & Mackey, 2008).
Therefore, understanding the metabolic transformation of cancer cells may
eventually lead to the development of therapies against CRC. In addition, an antiCRC therapy like butyrate may be effective, but further research is needed to
understand its metabolism and functions in cancerous colonocytes.
1.3.3. Butyrate Metabolism in Colorectal Cancer Cells
As the preferred energy substrate, butyrate increases cell metabolism and
proliferation of normal colonocytes. However, in cancerous colonocytes, butyrate
inhibits cell proliferation and induces apoptosis. This opposing effect of butyrate
on the proliferation in normal versus cancerous colonocytes is known as butyrate
paradox (Bultman, 2014a; Leonel & Alvarez-Leite, 2012). Previous publications
emphasized that the butyrate paradox may result from the differences in butyrate
concentration and exposure time across the studies and the cell’s ability to
oxidize butyrate (Hamer et al., 2008; Leonel & Alvarez-Leite, 2012).
Since colonocytes metabolize butyrate as their primary energy source,
metabolic transformation in cancerous colonocytes significantly changes
butyrate’s metabolic fates (Hague et al., 1997). According to Donohoe et al.
(2012), normal colonocytes metabolize butyrate through the mitochondrial
oxidative pathway; however, cancerous colonocytes undergo high levels of
glycolysis with a reduction in mitochondrial OXPHOS (the Warburg effect)
(Figure 11) (Donohoe, Collins, et al., 2012; Donohoe et al., 2013). As a result,
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butyrate accumulates in the nucleus and acts as an HDACi to control genes that
inhibit cell proliferation and increase apoptosis (Donohoe et al., 2013).
Interestingly, inhibition of the Warburg effect and addition of butyrate stimulates
proliferation in a way that resembles normal colonocytes (Donohoe, Collins, et
al., 2012). However, butyrate-stimulated proliferation was dependent upon low
levels (0.5-1 mM), whereas butyrate reduces proliferation and increases
apoptosis at high concentrations (2-5 mM) (Donohoe, Collins, et al., 2012). This
was consistent with the previous observation that 1-2 mM is the oxidative
capacity of these cells (Andriamihaja et al., 2009). Thus, at levels higher that 2
mM, butyrate accumulates in the nucleus instead of being oxidized, and acts as a
HDACi both in normal colonocytes and cancerous colonocytes (Donohoe et al.,
2013). These 0.5~5 mM concentration range in their studies is physiologically
relevant because butyrate’s approximate concentration is ~30 mM in the lumen
of colon (Donohoe et al., 2013; M Astbury & M Corfe, 2012). Overall, the
metabolic fate of butyrate in colonocytes is significantly involved in its function as
an energy source or HDACi.
Previous studies observed altered gene expression of the metabolic
enzymes relating to the mitochondrial functions and butyrate β-oxidation in CRC
(K. Y. Fung, Cosgrove, Lockett, Head, & Topping, 2012; Kitahara et al., 2001).
One study investigated the gene expression in CRC throughout progression and
different stages; they found genes involved in metabolism, particulatly
mitochondrial metabolism, are the most commonly altered (22%) (BirkenkampDemtroder et al., 2002). They also found that lipid metabolism related genes are
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mainly down-regulated, and expression of SCAD is significantly decreased in all
stages of CRC (Birkenkamp-Demtroder et al., 2002). Since SCAD catalyzes the
first step of butyrate oxidation, decreased SCAD may influence butyrate
metabolism and subsequent change in butyrate roles (M Astbury & M Corfe,
2012; van Maldegem et al., 2006).
In summary, the dysfunction of mitochondrial β-oxidation system and
reduced gene expression of related enzymes in CRC may change butyrate
metabolism in the colonocytes. Since the metabolic fate of butyrate in
colonocytes is highly related to its function, further understanding of butyrate
metabolism in cancerous colonocytes is strongly suggested to understand its role
as an HDACi and ability to exert anti-cancer effects against CRC.
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Table 1 Definitions of dietary fiber
Organization

Definition

Hipsley
(1953)

Non-digestible constituents making up the plant cell wall.

FAO/WHO
(1995)

The edible plant or animal material not hydrolyzed by the endogenous
enzymes of the human digestive tract as determined by the agreed upon
method.

AACC
(2000)

The edible parts of plants or analogous carbohydrates that are resistant to
digestion and absorption in the human small intestine with complete or
partial fermentation in the large intestine. Dietary fiber includes
polysaccharides, oligosaccharides, lignin and associated plant substances.
Dietary fibers promote beneficial physiological effects including laxation,
and/or blood cholesterol attenuation, and/or blood glucose attenuation.

NAS
(2002)

Dietary fiber consisting of non-digestible carbohydrates and lignin that are
intrinsic and intact in plants. Functional fiber consisting of isolated, nondigestible carbohydrates which have beneficial physiological effects in
humans, and Total Fiber as the sum of Dietary fiber and Functional Fiber.

CAC
(2006)

Defined dietary fiber as: carbohydrate polymers with a degree of
polymerization not lower than three, which are neither digested nor
absorbed in the small intestine. Dietary fiber consists of one or more of:
edible carbohydrate polymers naturally occurring in the food as consumed;
Carbohydrate polymers obtained from food raw material by physical,
enzymatic, or chemical means; Synthetic carbohydrate polymers.
(Continued on the next page)
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Table 1 Continued.
Organization

Definition

CCNFSDU
(2008)

Dietary fiber is carbohydrate polymers with 10 or more
monomeric units, which are not hydrolyzed by endogenous
enzymes in the small intestine of human beings and belong to
following categories: Edible carbohydrate polymers naturally
occurring in food as consumed; Carbohydrate polymers,
which have been obtained from raw material in food by
physical, enzymatic, or chemical means and which have been
shown to have physiological effects of benefit to health by
generally accepted scientific evidence to competent
authorities; Synthetic carbohydrate polymers, which have
been shown to have physiological effect of benefit to health by
generally accepted scientific evidence to competent
authorities.
The definitions of dietary fibers from the different organizations are listed.
FAO/WHO; Food and Agriculture Organization of United Nations and World
Health Organization, AACC; American Association of Cereal Chemists, NAS;
National Academy of Science, CAC; Codex Alimentarius Commission,
CCFNSDU; Codex Committee on Nutrition and Foods for Special Dietary Uses.
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Table 2 Dietary fiber in the diet
Origin
Natural

Source
Plants

Fiber element
Indigestible polysaccharides

Resistant
oligosaccharides

Algal

Synthesized

Non-starch
polysaccharides
(NSP), Cellulose,
Hemicellulose
Sugar acids (pectin)
β-glucans
Frutans
(inulin, fructooligosaccharides)

Analogous
carbohydrates
Lignin

Resistant starch
Resistant dextrin
Lignin

Components of
plants

Suberin, Waxes, Cutin,

Indigestiblepolysaccharides

Gums
Mucilages

Animals
Artificial

Sub- fiber element

Resistant
oligosaccharides

Analogous
carbohydrates
(=carbohydrate
polymers)

Chitin, Chitosan,
Collagen, Chondroitin
Frutans
: Fructooligosaccharides
Galactooligosaccharides
Resistant starch
Resistant dextrin
Modified cellulose
Polydextrose

Foods source
fruits, vegetables,
cereals, wheat
bran, grains,
nuts, legumes

burdock, chicory,
dandelion root,
leeks, onions,
asparagus
carbohydratecontaining foods
fruits, vegetables,
cereal grains
fruits, vegetables
seeds plants,
seaweed and
plants extract
yeasts,
invertebrates
fortified foods,
carbohydratecontaining foods

fortified foods,
carbohydratecontaining foods

Dietary fiber is listing based on the origin (natural- or artificial- occurring). Then, it
is categorized depend on the source (plants, algal, animals and/or synthesized).
All fiber elements and sub-fiber elements are listed along with food sources.
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Table 3 General classification of dietary fiber
Physicochemical
property
Solubility

Degree and dietary fiber
High
Pectin, β-glucan, Gums,
Polydextrose, Inulin

Viscosity

Fermentability

High
Pectin, β-glucan, Gums,
Mucilages
Well
Pectin, β-glucan, Gums, Inulin,
Resistant starch, Non-starch
polysaccharides (NSP), Resistant
Oligosaccharides, Polydextrose,
Chondroitin

Low
Wheat bran, cellulose,
Some hemicellulose, Lignin
Low
Cellulose, Hemicellulose,
Lignin
Poor- or partial
Cellulose, Hemicellulose,
Lignin, Cutin, Suberin,
Waxes, Chitin, Chitosan,
Collagen

Dietary fiber is differentiated regarding their physicochemical properties including
solubility, viscosity and fermentability.
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Table 4 Summary of epidemiological studies regarding on the
consumptions of DF and CRC incidence
Design
Study

Dietary
fiber

Conclusion

Year

Protective effects
Trock, Lanza, &
Greenwald

Howe et al.

Bingham et al.

Dahm et al.

meta-analysis
fibers,
Fiber-rich diets provide the
(37 observational vegetables, protective effects against CRC
studies, 15 case- grains or
control studies)
fruits
combined
fibers
Intake of fiber-rich foods is
analysis (13
inversely associated with the risk of
case-control
CRC
studies)
observational
fibers
DFs in foods was inversely related
study
to large bowel cancer incidence
(N=519,978)

prospective
case-control
study (N=579)
No and/or weak associated
Fuchs et al.
prospective
study
(N=88,757)
Michels et al.
prospective
study &
combined
analysis (2
cohort studies)
Romaneiro &
cohort study
Parekh
(N=45,491)

1990

1992

2003

fibers

Consumption of DFs has inverse
association with CRC risk

2010

fibers

There is no supportive evidence on
the protective effects of DFs to
CRC incidence
Consumption of fruits and
vegetables dose not shown
protective effect to CRC

1999

Relatively low intake of DFs has
weak association with CRC risk

2012

fruits and
vegetables

fibers

Changeable depending on variables
Terry et al.
cohort study
fruits and
No association between cereal fiber
(N=61,463)
vegetables, and CRC risk, but low consumption
cereal fiber of fruits and vegetables have the
greater risk of CRC
Park et al.
pooled analysis
fibers
In aged-adjusted cases, DFs
(prospective
inversely related to CRC. But, with
cohort studies)
accounting with other dietary risk
factors, there is no association
Aune et al.
systematic
Fruits and
High intake DFs, particularly cereal
review & metavegetables, fiber and whole grains has inverse
analysis (25
legume,
association with CRC, whereas
prospective
cereal
other fibers have weak association
studies)
fibers,
whole
grains

2000

2001

2005

2011

Based on their conclusions, epidemiological studies are divided into the three
categories; protective effects, no and/or weak associated, and changeable
depending on variables. DF; dietary fibers, CRC; colorectal cancer.
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Table 5 The molecular and cellular alterations in cancer cells that leads
metabolic transformations
Altered mechanism

Detail
mechanisms

Activated
signaling
pathway

PI3K/Akt

mTOR
Gene expression Activation of
(activated or loss) HIFα

Activation of cMyc

Loss of p53

Expression of
enzyme and
protein
(increased)

LDH

Results

 glucose transporter expression ↑
 glycolytic enzymes expression ↑ (e.g.
hexokinase)
 glucose-carbon flux into biosynthetic
pathways ↑ (e.g. direct regulation of ACL
activity)
 lipogenic gene expression ↑ (e.g.
SREBP-1, ACL, ACC and FAS)
 β-oxidation and fatty acids degradation ↓
 activation of mTOR pathway
 protein synthesis and cell growth ↑
 glucose transporter expression ↑
 aerobic glycolytic enzymes expression ↑
(e.g. PDK and LDH)
 promotion of aerobic glycolysis &
reduction of OXPHS
 activation of PI3K/Akt pathway
 glucose transporter expression ↑
 aerobic glycolytic enzymes expression ↑
(e.g. PDK and LDHA)
 promotion of aerobic glycolysis &
reduction of OXPHS
 glycolysis ↑
 expression of enzymes related to
OXPHS ↓
(e.g. cytochrome C oxidase 2)
 conversion of pyruvate into lactate ↑

 inactivation (=phosphorylation) of PDH ↑
 import of pyruvate into the TCA cycle ↓
ACL
 conversion cytosolic citrate into acetylCoA and OAA ↑
 fatty acids and lipid synthesis ↑
The altered molecular and cellular metabolism that leads cancer cells to attain high
rates of aerobic glycolytic systems and efficient biosynthetic mechanisms. PI3K;
phosphatidylinositol 3’ kinase, ACL; ATP-citrate lyase. mTOR; mammalian target of
rapamycin, SREBP-1; sterol regulatory element-binding protein-1, ACC; acetyl-CoA
carboxylase, FAS; fatty acid synthase, HIFα; hypoxia-inducible factor α, PDK;
pyruvate dehydrogenase kinase, LDH(A); lactate dehydrogenase (A), OXPHS;
oxidative phosphorylation, PDH; pyruvate dehydrogenase, OAA; oxaloacetate.
PDK
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Figure 1 Vogelgram of colorectal cancer
Involvement of four main gene’s alteration (bolds) related to CRC development
and subsequent signaling pathways from (in) activation of those genes are
shown (▲: activated, ▼: inactivated). Consequent events that influence on cell
proliferation and apoptosis resulting in formation of aberrant crypt foci, adenoma
and carcinoma are described at the bottom (↑: increase, ↓: decrease). At the
beginning of CRC development, inactivation of APC gene triggers the
adenomatous process. Next, activation of K-Ras is required to promote the
growth of adenoma. Mutations in SMAD 2/4 and TP53 give rise to tumor
expansion and malignant transformation of CRC. APC denotes adenomatous
polyposis coli, MAPK mitogen-activated protein kinases, TGF-β transforming
growth factor-β.
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Figure 2 Risk factors of colorectal cancer.
The risk factors toward CRC are shown. It includes non-modifiable factors (age,
gender, family history and individual history), modifiable factors (lifestyle-related
and dietary factors) and semi-modifiable factor (metabolic diseases). The box
with each risk factor has a summary of the facts that increase or decrease the
susceptibility of CRC development. The Solid line and box represent a positive
association with CRC and the dotted line and box represent a negative
association with CRC.
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Figure 3 Dietary recommendations to prevent CRC development
To reduce CRC risk, several dietary interventions can be suggested. Less intake
of red and processed meat, saturated fat and animal fat decrease CRC
development. More intake of dietary fiber, whole grains, and fruits and
vegetables reduce CRC incidence. In addition to these dietary factors, moderate
energy intake focusing on variety, nutrients density and amounts of diet can be
suggested to improve CRC incidence.
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Figure 4 The beneficial physiological effects of dietary fiber and its
underlying mechanisms.
Based on their physicochemical properties (▲: relatively high, ▼: relatively low),
DF is responsible for a variety of physiological effects. These effects are mainly
involved in the improvement of blood glucose and lipid metabolism, laxation,
overall improvement of colonic status and reduced risk in CRC development (↑:
increase, ↓: decrease). CRC; colorectal cancer, SCAFs; short-chain fatty acids.
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Figure 5 The beneficial physiological influences from gut microbiota and its
underlying mechanisms
Gut microbiota supply various metabolites from DF fermentation. Those
bacterial-derived metabolites, SCFAs and gases are involved in the maintenance
of colonic health and homeostasis, and host energy metabolism. Also, they are
related to CRC incidence through diverse physiological routines (↑: increase, ↓:
decrease). DFs; dietary fibers, SCFAs; short-chain fatty acids, CRC; colorectal
cancer, E; energy, ETC; electron transport chain.
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Figure 6 The influential factors on the composition of gut microbiota and
its impacts on the maintenance of colonic health and CRC development.
Several factors can impact on the maintenance and/or change of the gut
microbiota composition in terms of diversity, number and their activity. The
condition of the host (genetic, age, stress), diseases (IBDs, obesity, diabetes),
diet (HFD and DFs), and environmental factors (antibiotic therapy) can alter the
composition of gut microbiota. The transformation of gut microbiota is directly
related to colonic homeostasis and their outcomes (bacterial-derived metabolites)
in respect of the types and amounts. Interruption of microbial homeostasis can
change the population of gut microbiota, and produce the potential carcinogenic
molecules and toxic compounds leading to CRC incidence. Therefore, the
balance of gut microbiota is important in maintaining gut microbiota’s
homeostasis, colonic conditions, and host health. IBDs; inflammatory bowel
disease, HFD; high-fat diet, DFs; dietary fibers, CRC; colorectal cancer.
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Figure 7 The pathways of butyrate production and the related butyrateproducing bacteria in the colon.
In the human colon, several bacteria participate in butyrate production and two
major pathways are utilized by them. According to enzymes that they utilize at
the end of pathway, butyrate-producing bacteria can be categorized into either
CoA-transferase pathway or butyrate kinase pathway. The overall butyrate
biosynthesis pathway and the involved bacteria are shown. DHAP;
dihydroxyacetonephosphate, PEP; phosphoenolpyruvate, DFs; dietary fibers
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Figure 8 Two distinct mechanisms of butyrate in the histone acetylation.
(A) Butyrate presents in a gradient through the crypts (upper ~ base) due to the
mucosal flow. The gradient concentration of butyrate relates the butyrate
mechanisms in histone acetylation. Near the lumen, colonocytes are exposed to
high doses of butyrate (5mM). In here, butyrate increases cell apoptosis and
decreases proliferation as HDAC inhibitor (ACL-independent mechanism) to
exfoliate. Whereas, at the bottom of the crypts, butyrate concentration is
relatively lower (0.5mM). At this locations, butyrate is metabolized via
mitochondrial β-oxidation and produces acetyl-CoA. As cofactor (acetyl-CoA) for
HATs, butyrate regulates histone acetylation leading to an increase in cell
proliferation and decrease in cell apoptosis (ACL-dependent mechanism). It may
associate with butyrate’s roles in the turnover of colonic epithelial cells to
maintain colonic homeostasis. (B) The graph shown above is to explain
butyrate’s two distinct mechanisms in histone acetylation depending on its
concentration. ACL; ATP-citrate lyase, HATs; histone acetyltransferase, HDACs;
histone deacetylase.
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Figure 9 The roles of butyrate in various mechanisms related to maintain
colonic- and/or host health.
As an energetic substrate, epigenetic regulator, and ligand, butyrate plays a role
in many mechanisms to maintain colonic- and host health. Butyrate produces
ATP for colonic epithelial cells and the host. It also acts on signaling and
mechanisms to exert anti-inflammatory and anti-oxidative stress effect. In
addition, butyrate is involved in body weight regulation through activation of
GPCRs, and controls gene expressions as HDAC inhibitor to show anti-cancer
effects. SCFAs; short chain fatty acids, ATP; adenosine triphosphate, GPCR; Gprotein-coupled receptor, HDACi; histone deacetylase inhibitor, ROS; reactive
oxygen species, PYY; intestinal peptide YY, GLP-1; glucagon-like peptide 1.
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Figure 10 The metabolic transformation in cancer cells.
From the high glycolytic metabolism rate, cancer cells can get massive amounts
of biosynthetic substrates to meet their rapid growth and cellular expansions. The
pentose phosphate pathway generates the nucleotides (ribose-5-phosphate) for
RNA and DNA synthesis, and NADPH for lipid synthesis. Cytosolic citrate divides
into acetyl-CoA and oxaloacetate that are necessary for fatty acids and amino
acids synthesis, respectively. G-6-P; glucose-6-phosphate, 6-G-gluconate; 6phosphogluconate, PEP; phosphoenolpyruvate, α-KG; α -ketoglutarate, OAA;
oxaloacetate, TCA; tricarboxylic acid, AAs; amino acids, NADP; nicotinamide
adenine dinucleotide phosphate, RNA; ribonucleic acid, DNA; deoxyribonucleic
acid, LDHA; lactate dehydrogenase A, PDH; pyruvate dehydrogenase, ACL;
ATP-citrate lyase.
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Figure 11 The different metabolisms of butyrate and roles between normal
colonocytes and cancerous colonocytes.
Normal colonocytes utilize butyrate as a major energy source because butyrate
enters mitochondrial β-oxidation and yields ATP. In contrast, because of the
Warburg effect, cancerous colonocytes metabolize glucose over butyrate
resulting in butyrate accumulation in the nucleus. In the nucleus, butyrate
regulates genes that reduce proliferation and increases apoptosis as an HDAC
inhibitor. ACL; ATP-citrate lyase, HATs; histone acetyltransferase, HDAC;
histone deacetylase, ATP; adenosine triphosphate, TCA cycle; tricarboxylic acid
cycle.
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CHAPTER II
CELLULAR METABOLISM AND DOSE REVEAL CARNITINEDEPENDENT AND -INDEPENDENT MECHANISMS OF
BUTYRATE OXIDATION IN COLORECTAL CANCER CELLS
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A version of this chapter was originally published by Anna Han, Natalie
Bennett, Amber MacDonald, Megan Johnstone, Jay Whelan, and Dallas R.
Donohoe entitled “Cellular Metabolism and Dose Reveal Carnitine -Dependent
and -Independent Mechanisms of Butyrate Oxidation in Colorectal Cancer Cells”
Journal of Cellular Physiology. 9999:1-10 (2015).
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2.1 Abstract
Dietary fiber has been suggested to suppress colorectal cancer
development, although the mechanisms contributing to this beneficial effect
remain elusive. Butyrate, a fermentation product of fiber, has been shown to
have anti-proliferative and pro-apoptotic effects on colorectal cancer cells. The
metabolic fate of butyrate in the cell is important in determining whether, it acts
as an HDAC inhibitor or is consumed as a short-chain fatty acid. Non-cancerous
colonocytes utilize butyrate as the primary energy source whereas cancerous
colonocytes increase glucose utilization through the Warburg effect. In this study,
we show that butyrate oxidation is decreased in cancerous colonocytes
compared to non-cancerous colonocytes. We demonstrated that colorectal
cancer cells utilize both a carnitine-dependent and carnitine-independent
mechanism that contributes to butyrate oxidation. The carnitine-dependent
mechanism is contingent on butyrate concentration. Knockdown of CPT1A in
colorectal cancer cells abolishes butyrate oxidation. In terms of selectivity, the
carnitine-dependent mechanism only regulated butyrate oxidation, as acetate
and propionate oxidation were carnitine-independent. Carnitine decreased the
action of butyrate as an HDAC inhibitor and suppressed induction of H3
acetylation by butyrate in colorectal cancer cells. Thus, diminished oxidation of
butyrate is associated with decreased HDAC inhibition and histone acetylation. In
relation to the mechanism, we find that dichloroacetate, which decrease
phosphorylation of pyruvate dehydrogenase, increased butyrate oxidation and
that this effect was carnitine-dependent. In conclusion, these data suggest that
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colorectal cancer cells decrease butyrate oxidation through inhibition of pyruvate
dehydrogenase, which is carnitine-dependent, and provide insight into why
butyrate shows selective effects toward colorectal cancer cells.

2.2 Introduction
Diet is one of the risk factors associated with colorectal cancer
susceptibility and dietary modifications have been proposed to lower colorectal
cancer incidence and mortality (Bruce, Wolever, & Giacca, 2000; RyanHarshman & Aldoori, 2007; Safari, Shariff, Kandiah, Rashidkhani, & Fereidooni,
2013; Vargas & Thompson, 2012; Vargas et al., 2012; Willett, 2001). Several
studies have shown that consumption of a high-fiber diet is associated with a
reduction in colorectal cancer incidence and development (Bingham et al., 2003;
Giovannucci, Stampfer, Colditz, Rimm, & Willett, 1992; Reddy, 1999; Schatzkin
et al., 2007). In contrast, several other human epidemiological studies have failed
to demonstrate a beneficial effect toward preventing colorectal cancer (Fuchs et
al., 1999; Lanza et al., 2007; Mai et al., 2003). Thus, the role of dietary fiber in
colorectal cancer prevention remains unclear and unresolved. The major
metabolites derived from fiber include acetate, propionate, and butyrate. Of these
metabolites, butyrate has been proposed to be a primary candidate in fiber’s
suppressive effects toward colorectal cancer (Louis, Hold, & Flint, 2014;
Wollowski, Rechkemmer, & Pool-Zobel, 2001). Butyrate is a short-chain fatty
acid, produced in the colon by bacteria through fermentation of fiber, and is the
preferred energetic substrate of the colonocytes (Donohoe et al., 2011; Flint,
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Scott, Duncan, Louis, & Forano, 2012; WE Roediger, 1980). In addition, to
butyrate’s role as an energetic substrate in colonocytes, butyrate inhibits cell
growth, promotes cellular differentiation, and induces apoptosis in cancer cells in
vitro at physiologically relevant doses (Archer, Meng, Shei, & Hodin, 1998;
Chopin, Toillon, Jouy, & Bourhis, 2002; Velcich et al., 1995).
Several previous studies have demonstrated that, the ability of butyrate to
inhibit cell proliferation and induce apoptosis is directly associated with its
metabolic fate (Andriamihaja, Chaumontet, Tome, & Blachier, 2009; Donohoe et
al., 2012; Leschelle, Delpal, Goubern, Blottiere, & Blachier, 2000). Specifically, in
colorectal cancer cells, increased glycolysis or the Warburg effect regulated the
intracellular butyrate level, which was associated with butyrate inducing proapoptotic genes through inhibition of histone deacetylases (HDACs; (Donohoe et
al., 2012)). As an alternative to inhibiting HDACs, butyrate was oxidized
completely through the Krebs cycle (to CO2) or butyrate directly gave rise to
cytosolic acetyl-CoA (through citrate originating from the mitochondria). Cytosolic
acetyl-CoA then donated acetyl groups to histone acetyltransferase (HATs) to
regulate gene expression or it was used for de novo lipogenesis (Andriamihaja et
al., 2009; Donohoe et al., 2012; Leschelle et al., 2000; Wellen et al., 2009). Thus,
to understand butyrate’s inhibitory and selective effects toward colorectal cancer,
it is essential to characterize the mechanisms that regulated butyrate oxidation.
Carnitine and the carnitine palmitoyltransferase (CPT) system regulate
fatty acid transport into the mitochondria. The CPT system, which utilizes
carnitine palmitoyltransferase 1 (CPT1), carnitine acyltransferase, and carnitine
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palmitoyltransferase 2 (CPT2), transports fatty acids across the outer and inner
mitochondrial membranes into the matrix, and has been long known to have
selectivity toward transporting long-chain fatty acid (Fritz, 1961). In the first
reaction, carnitine palmitoyltransferase 1 (CPT1), uses carnitine for its transport
mechanism as it converts the fatty acyl-CoA into the fatty acyl-carnitine ester.
The fatty acyl-carnitine, is then shuttled through the CPT system/transporter into
the mitochondrial matrix. In the final step, CPT2 converts the fatty acyl-carnitine
back into the original fatty acyl-CoA, which is released in conjunction with
carnitine into the matrix. This transport process is considered the major ratecontrolling step in fatty acid oxidation (Ceccarelli, Chomienne, Gubler, & Arduini,
2011). The uptake of butyrate and other short-chain fatty acids (SCFAs) into the
mitochondria has been shown not to require carnitine or the CPT system
(Ceccarelli et al., 2011; Fritz, 1959, 1961). However, it is important to recognize
that many of these earlier studies that characterized fatty acid oxidation utilized
lower SCFA concentrations (in the micromollar range), and cell-types, such as
heart and liver, where SCFAs are not the primary energy source under
physiological conditions. Thus, in the case of butyrate oxidation in the
colonocytes, where colonic butyrate level reach millimolar concentrations, and
butyrate serves as the preferential energetic substrate by the colonocytes, it is
unknown as to whether carnitine and the CPT system, impact the oxidation of
butyrate.
In the study, experiments were performed to distinguish butyrate oxidation
in the cancerous and non-cancerous colonocytes, while also further
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characterizing the mechanisms that impact oxidation of butyrate in the cancerous
colonocytes, and thus influence butyrate’s action as an HDAC inhibitor.
Cancerous colonocytes showed diminished butyrate oxidation compared to noncancerous colonocytes. This result coincided with lower intracellular carnitine
levels and decreased levels of organic cation/carnitine transporter 2 (OCTN2), a
major carnitine transporter, in the cancerous colonocytes compared to noncancerous colonocytes. As a consequence, the role of carnitine in regulating
butyrate oxidation in the cancerous colonocytes was interrogated further. Toward
this end, butyrate oxidation was found to be both carnitine-dependent and
carnitine-independent in the cancerous colonocytes. Furthermore, the carnitinedependent regulation of butyrate oxidation was mediated through the
phosphorylation of pyruvate dehydrogenase, which is a major contributor to the
Warburg effect (Fan et al., 2014; Hitosugi et al., 2011). This study provides an
initial framework into understanding how shifts in cellular mechanism alter the
fate of microbial-derived butyrate and determine its selective effects toward the
colorectal cancer cell.

2.3 Materials and Methods
2.3.1. Cell culture and transfections
HCT116 cells (ATCC, CCL-247) were grown in DMEM formulated with
25mM glucose and 10% FBS. FHC cells (ATCC, CRL-1831) were grown in
DMEM:F12 medium with 20% FBS. RNAi transfection in HCT116 cells was
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performed as described (Donohoe et al., 2012), and siRNA pools for human
Cpt1a (Dharmacon, L-009749-00), and siMock non-targeting control
(Dharmacon, D-001810-01-05) were used at a 20nM final concentration. The
optimized time for each siRNA transfection was confirmed with Western blotting.
2.3.2. Flux experiment
XF24 Analyzer (Seahorse Bioscience) was used to measure % change in
the oxygen consumption rates (% OCR) in HCT 116 and FHC cells. Experiments
were conducted following manufacturer guidelines. Cells (FHC and HCT116
cells) split and seeded (at an identical cell number per well) into XF24 cell culture
microplates (Seahorse Bioscience, 100777-004). Before running seahorse, cell
plates are incubated with 1X KHB (2.5mM glucose, with or without 50μM
carnitine) in non-CO2 incubator at 37℃ for 1h. All Seahorse experiments were
run with identical condition (unless otherwise noted). Briefly, KHB media or short
chain fatty acids (SCFAs) including sodium acetate, propionate or butyrate
(Sigma P1880, S8750 and B5887) at 1 and/or 5mM final concentration were
injected and the change in OCR was measured from baseline (%OCR). Next, 2deoxyglucose (Sigma, D8375) was injected and %OCR was measured again.
Finally, 10% sodium azide was injected to block Complex Ⅳ and mitochondrial
respiration. Azide was used as a positive control to show that mitochondrial
respiration is responding as expected and our compounds have an effect on
mitochondrial function. In all cases, azide decreased OCR to at or below baseline
respiration. As we were initially developing the methodology to measure butyrate
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oxidation with the Seahorse we did not use azide. When testing other cell lines
(non-colonocyte) we found that they showed no response butyrate. However,
they did response to azide (OCR dropped), thus suggesting that the lack of
response to butyrate was real, and not an artifact of the Seahorse technology. In
some situations, additional chemical compounds were injected: etomoxir (Tocris
Bioscience, Minneapolis, MN, 4539), palmitate/or BSA from XF Palmitate-BSA
FAO substrate kit (Seahorse Bioscience, #102720-100), and 5mM DCA (Sigma,
347795).
2.3.3. Western blotting
Proteins from FHC and HCT116 cells were extracted with RIPA buffer
(Cell Signaling, #9806), 1mM PMSF (Cell Signaling, #8553) and phosphatase
inhibitor cocktail (Cell Signaling, #5872). Protein concentrations were measured
by Bradford assay. Gel electrophoresis and transfer were conducted using
standard protocol for Western blot. Antibodies that were used included panacetylated-histone H3 (Active Motif, Cat#39139), total Histone H3 (Active Motif,
Cat#39736), MCT1-c terminal (Abcam, Cat# ab179832), OCNT2 (Abcam, Cat#
ab79964), CPT1A (Cell Signaling, Cat# 122525), phospho-PDH E1- α (S293)
(Abcam, Cat# ab92696), PDH E1- α (Abcam, Cat# ab110330), and β-actin
(Sigma, Cat# A1978). Chemiluminescence or fluorescent detection was
performed with the Odyssey Fc and bands were quantified with Image Studio
Software (LI-COR Biosciences, Lincoln, NE).
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2.3.4. Carnitine assay
Carnitine levels in FHC and HCT116 cells were measured with a carnitine
assay kit (Biovision, K642-100). Conditions were kept identical to the Seahorse
experiments. The assay was performed as described the protocol from the
manufacturer. Cells were deproteinized immediately before the assay with a PCA
deproteinization kit (Biovision, K808-200). The carnitine contents in cells were
normalized to protein amounts.
2.3.5. Statistical analysis
For biochemical assays, Seahorse Experiments, and Western blots, the
differences between experimental groups were determined by ANOVA followed
by a Turkey post-hoc test. All data are expressed as mean ± SE.

2.4 Results
2.4.1. Diminished butyrate oxidation in colorectal cancer cells
To test whether butyrate oxidation is altered in colorectal cancer cells
compared to non-cancerous colonocytes, we first sought to develop methodology
that would allow us to analyze butyrate oxidation over time, and to probe the
mechanisms that regulated the process in more detail. Therefore, we utilized the
Seahorse XF24 Analyzer to measure changes in the oxygen consumption rate
(OCR) in cultured cells. In all of our Seahorse experiments, the assay is run in
KHB media, were the only exogenous energetic substrate is glucose (2.5mM).
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Thus, initial OCR measurements represent glucose oxidation. Injection of
butyrate results in both butyrate and glucose contributing to OCR. To block
glucose oxidation, and thereby leave butyrate as the sole exogenous substrate
(butyrate oxidation), we decided to use 2-deoxyglucose (2DG), which is a
competitive inhibitor of glucose and abolishes glucose oxidation (Figure 12A).
We first tested this strategy utilizing HCT116 colorectal cancer cells. The %
change in the OCR was measured as cells were treated with increasing
concentrations of butyrate (0.5, 1.0, 2.0, and 5.0mM). Although the top three
doses were elevated over 0.5mM, there was no distinct dose-response
relationship. However, upon injection of 2DG (5mM) a dose-response could
clearly be identified, presumably as butyrate as the only exogenous substrate
available (Figure 12B). We then tested whether butyrate oxidation was different
between non-cancerous Fetal Human Colonocytes (FHC) and cancerous
HCT116 cells utilizing the same strategy. The % change in the oxygen
consumption rate was much greater in FHC compared to HCT116 cells,
suggesting that in general FHC have greater response to butyrate (Figure 12C).
Moreover, after addition of 2DG, the butyrate oxidation was much greater in FHC
compared to cancerous HCT116 cells (Figure 12D). This provided evidence that
butyrate oxidation is suppressed in cancerous colonocytes compared to noncancerous colonocytes.
Butyrate, uptake into the cell is accomplished through the
monocarboxylate transporter І (MCT І). We next tested whether the cancerous
cell line (HCT116) had diminished transport of butyrate compared to the non-
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cancerous cell line (FHC). However, when analyzing MCT І levels in the two cell
lines, we actually find that MCT І expression was higher in HCT116 cells
compared FHC. This suggests that butyrate uptake is not suppressed in HCT116
cells (Figure 12E).
2.4.2. Butyrate oxidation is regulated by carnitine-dependent and independent mechanism
Transport of SCFAs into the mitochondria is recognized to be independent
of carnitine palmitoyltransferase І (CPT І) (Ceccarelli et al., 2011; Fritz, 1961).
However, butyrate oxdiation has been shown to be elevated throughcarnitine
supplementation (Fritz, Kaplan, & Yue, 1962; Hird & Weidemann, 1966).These
conflicting results are likely due to differences in cell-type and SCFA
concentrations used in the studies. Nevertheless, we sought to determine
whether carnitine and CPT impacts butyrate oxidation in our system. First, we
measured intracellular carnitine levels in non-cancerous FHC and cancerous
HCT116 cells. With assay conditions kept identical to when we measured
butyrate oxidation, we found that the intracellular carnitine level was over 12
times higher in FHC compared to HCT116 cells. (303 vs. 24μmols/g of protein)
(Figure 13A). Next, we analyzed whether OCTN2, which is the major carnitine
transporter (Ohashi et al., 2001; Seth, Wu, Huang, Leibach, & Ganapathy, 1999;
Wu et al., 1999), is expressed differently in the FHC and HCT116 cells. The
expression of OCTN2 was found to be elevated in FHC compared to HCT116
cells (Figure 13B). To probe the role of carnitine in the oxidtaion of butyrate, we
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performed the assay with KHB media containing carnitine and compared it to
KHB media void of cartnitine. If butyrate oxdiation was carnitine-independent
then we postulated that oxidation should not be affected by absence of carnitine.
However, this was not the case, as the addition of 50μM carnitine to KHB media,
the % change in oxygen consumpation rate following HCT116 cells treated with
5mM butyrate was higher than KHB media without carnitine (Figure 13C). This
was especially evident after 2DG injection as the butyrate oxidation showed both
a carnitine-independent (even without carnitine, butyrate significantly increased
the %OCR) and carnitine-dependent responses (Figure 13D). To test whether
butyrate oxidation was carnitine-dependent at lower doses, we treated HCT116
cells with 1mM butyrate in the presence or absence of 50μM carnitine. At this
lower doses, 1mM HCT116 cells did not exhibit a carnitine-dependent response
(Figure 13E). Thus, butyrate oxidation was not significantly impacted by carnitine
(Figure 13F). These data reveal a carnitine-dependent mechanism that functions
at higher butyrate doses to regulate oxidation in the cell.
2.4.3. Carnitine-dependent mechanism is selective for butyrate oxidation
To gain further insight into the impact of carnitine on butyrate oxidation in
cancerous colonocytes, we tested increasing concentrations of carnitine (6, 12.5,
25, and 50μM) with a fixed butyrate dose (5mM). As carnitine concentrations
increased, so did the % change in the oxygen consumption rate after butyrate
treatment (Figure 14A). This dose-response was especially apparent after 2DG
treatment to block glucose oxidation, as butyrate oxidation was highest at 50μM
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(Figure 14B). We next sought to determine whether this carnitine-dependent
mechanism was prevalent for oxidation of other SCFAs. Thus, the major
objective of this experiment was to test how carnitine impacted the oxidation of
SCFAs, not how the oxidation of the SCFA differed from the each other. Using a
set SCFA concentration of 5mM, we found that treatment of colorectal cancer
cells (HCT116) with acetate or propionate failed to show the same carnitinedependent response as butyrate (Figure 14C). Moreover, only butyrate oxidation
was significantly affected by carnitine (Figure 14D). This suggests that the
carnitine-dependent oxidation is selective for butyrate in thses colorectal cancer
cells.
2.4.4. CPT1A-dependent oxidation of butyrate
Carnitine regulates fatty acid oxidation through carnitine
palmitoyltransferase (CPT), which transfers carnitine onto the fatty acid in
exchange for coenzyme A (CoA). We reasoned that since butyrate oxidation
was, in part, carnitine-dependent, at higher doses, then inhibiting or knocking
down CPT1A (the major isoform in colonocytes) would have a similar outcome as
taking away carnitine, where the oxidation of butyrate would be diminished. To
test this idea, we decided to inhibit CPT1A with the pharmacological agent
etomoxir, and transiently knockdown CPT1A with RNA interference. In the first
set of experiments, we treated HCT116 cells with etomoxir (ETO) after the 2DG
injection (so butyrate is the only available exogenous substrate), and found that
the % change in the oxygen consumption rate decreased (Figure 15A). Thus,
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butyrate oxidation was significantly diminished by the CPT1 inhibitor etomoxir
(Figure 15B). To further confirm CPT1 involvement and selectively target CPT1A,
we performed a time course knockdown of CPT1A in HCT116 cells. The time
course was meant to determine the maximal knockdown of CPT1A, and set the
conditions for the Seahorse assay. At 72hr, we observed maximal knockdown of
CPT1A protein (Figure 15C). To confirm fatty acid oxidation was decreased, we
conducted a series of experiments to test if palmitate oxidation was lower in cells
where CPT1A was knockdown. This was indeed the cases, as knockdown
CPT1A, completely abolished palmitate oxidation (Figure 15D). This result
showed us that knockdown of CPT1A was having a functional consequence on
fatty acid oxidation. We next tested whether butyrate oxidation was altered by
CPT1A knockdown in HCT116 cells. CPT1A knockdown diminished the change
in % oxygen consumption rate after butyrate injection (Figure 15E). CPT1A
knockdown completely blocked butyrate oxidation in HCT116 cells (Figure 15F).
These data point at role of CPT1A in regulating butyrate oxidation in the
colonocytes. This is consistent with CPT1A having diminished expression in
colorectal cancerous cells (HCT116) compared to non-cancerous colonocytes
(FHC) (Figure 19).
2.4.5. Lower butyrate oxidation results in elevated HDAC inhibition and H3
acetylation
As a result of diminished butyrate oxidation from lack of carnitine, we
hypothesized that suppressed butyrate oxidation, would increase butyrate
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concentration, and that would increase HDAC inhibition and histone acetylation.
We discovered that HDAC activity was diminished in cells treated with 5mM
butyrate whole media lacked carnitine (Figure 16A), thereby suggesting
enhanced inhibition of HDACs at this concentration of butyrate. Absence of
carnitine had no effect on HDAC activity for HCT116 cells treated with 1mM
butyrate. If inhibition of HDACs was indeed enhanced then histone acetylation
should be elevated. This was the case, as we demonstrated that HCT116 cells
treated with butyrate without carnitine had greater H3 acetylation (H3ac) than
cells treated with equal concentration of butyrate with carnitine (Figure 16B and
C).
2.4.6. Phospho-pyruvate dehydrogenase lowers oxidative metabolism and
butyrate oxidation
As cancer cells begin to increase glucose uptake and utilization through
the Warburg effect, the pyruvate dehydrogenase complex (PDH) becomes
inactive through phosphorylation of Ser 239 on the E1 subunit. We constructed a
model based on targeting phospho-pyruvate dehydrogenase as a central player
in mediating the diminised oxidation of butyrate in the colorectal cacner cells
(Figure 17A). In this simplified model, pyruvate is shunted toward lactate as PDH
becomes inactive through phosphorylation. The net result is lowered glucose
oxidation (per molecule of glucose taken up), and an overall decrease in
mitochondrial oxidation, including butyrate oxidation. In addition, elevated
glucose utilization, and glycolysis, suppres OCTN2 expression (this results in
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decreased carnitine uptake and concentration in cell), and lower butyrate
oxdiation through the carnitine- dependent mechanism. To test this model, we
used the compound dichloroacetate (DCA) to inhibit pyruvate dehydrogenase
kinase and decrease phosphorylation of PDH (increase in activity). Therefore,
treatment of colorectal cancer cells with DCA should increase butyrate oxidtion
through this mechanism. DCA behaved as expected in our cells, as DCA
inhibited phosphorylation of PDH (Ser 293) (Figure 17B). We next tested the
effects of DCA on glucose and butyrate oxidation. Consistent with the model,
initial injection of DCA (before butyrate oxidation), increased the % change in the
oxygen consumpation rate, demonstrating that DCA elevated oxidative
metabolism of glucose (Figure 17C), and butyrate oxidation (Figure 17D).
2.4.7. Link between phospho-pyruvate dehydrogenase and carnitine
To test whether there is a relationshipe between suppressed butyrate
oxidation from phospho-PDH and carnitine, we sought to find out if the elevated
butyrate oxdiation observed after DCA treatment was dependent in any way on
carnitine. We first tested whether DCA had a significant impact on OCNT2 and/or
CPT1A expression in cancerous HCT116 cells undergoing the Warburg effect.
DCA elevated OCTN2 and CPT1A epxression (Figure 18A) in HCT116 cells. We
then repeated the DCA experiemtns with and without carnitine, and analyzed
butyrate oxidation with the Seahorse XF24 analyzer. Removing carnitine fully
attenuated the butyrate oxidation response due to DCA treatment (Figure 18B).
DCA and carnitine were required for maximal response (Figure 18C). Taken
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together, these data point toward the phostphorlyation (and thus, inhibition) of
PDH as a key event in suppressing butyrate oxidation in the colorectal cancer
cell. This alos demonstrates that phosphorylation of PDH targets the carnitinedependent oxidation of butyraet through regulation of carnitine uptake and
expression of CPT1A.

2.5 Discussion
The colonocytes is unique because butyrate serves the role of being the
preferred energetic substrate (WE Roediger, 1980). It is also recognized that,
cancerous colonocytes shift their metabolism toward increased glucose uptake
and utilization as suggested by FDG uptake in Positron Emission Tomography –
Computed Tomography (PET-CT) scans (de Geus-Oei et al., 2006; Delbeke &
Martin, 2011; Kawada et al., 2015; van Kouwen et al., 2006). The change in
cellular metabolism toward glucose utilization and the Warburg effect alters
butyrate metabolism in the cell (Andriamihaja et al., 2009; Donohoe et al., 2012;
Leschelle et al., 2000). As a result, butyrate levels in the cells are affected, as it
inhibition of histone deacetylase (HDACs) by butyrate (Donohoe et al., 2012;
Donohoe et al., 2014; Leschelle et al., 2000). In this regard, suppression of cell
proliferation and induction of apoptosis in colorectal cancer cells by butyrate has
been associated with inhibition of HDACs (Archer et al., 1998; Chopin et al.,
2002; Velcich et al., 1995). Therefore, it is essential to characterize the oxidation
of butyrate in the cancer cell to understand the impact of butyrate as an HDAC
inhibitor. If cancer cells are predisposed to accumulate butyrate compared to
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normal colonocytes under the proper conditions, this could help explain why
cancer cells are sensitive to fiber diets.
In the work presented here, we define a diminished oxidation of butyrate in
cancerous colonocytes and interrogate mechanism(s) that include carnitine and
pyruvate dehydrogenase. We also demonstrate that with lower butyrate
oxidation, HDAC inhibition and histone H3 acetylation increase in colorectal
cancer cells.
Previous studies have defined a role for carnitine in the oxidation of longchain fatty acids, and short-chain fatty acid oxidation is mainly accepted to be
carnitine-independent (Ceccarelli et al., 2011; Fritz, 1959, 1961). In contrast, we
find butyrate oxidation to be partially carnitine-dependent in cancerous
colonocytes. This difference can be attributed to doses or concentrations of
butyrate use, where butyrate concentrations were in the micromollar range. In
our case, we used 5mM butyrate, which is a physiologically relevant
concentration in the colon. Toward this end, we demonstrate at 1mM there is no
carnitine-dependent mechanism involved in butyrate oxidation. This is consistent
with the carnitine-dependent mechanism only functioning at higher butyrate
doses, and this mechanism only being physiologically relevant to the colon. De
Preter et al. (2011) fount that carnitine did not enhance the oxidation of 1mM

14C-

butyrate to 14CO2 in colonic biopsies from normal and ulcerative colitis patients
(De Preter et al., 2011). A previous publication found that carnitine elevated
butyrate oxidation in an ADP-dependent fashion (Hird & Weidemann, 1966).
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The fact that carnitine levels were lower in HCT116 cells compared to
FHC cells suggest that carnitine may be an important determinant in lowered
butyrate oxidation observed in HCT116 cells. Thus, in addition to diminished
butyrate-producing bacteria and butyrate levels that has been observed in
colorectal cancer patient (Balamurugan, Rajendiran, George, Samuel, &
Ramakrishna, 2008; Wang et al., 2012), butyrate oxidation may be decreased
due to a reduction in carnitine in the colorectal cancer cell. We find that OCTN2,
the major carnitine transporter, is higher in FHC compared to HCT116 colorectal
cancer cells. This is consistent with a previous report that highlights a
downregulation in OCTN2 in cancer cells, in general (Scalise et al., 2012). The
mechanism causes the diminished carnitine level and decreased OCTN2 in
cancer cells is unknown; however, it is interesting to consider increased
glycolysis and diminished oxidative metabolism as a plausible starting point.
Dichloroacetate (DCA) is a compound that has been used to decrease the
phosphorylation of pyruvate dehydrogenase, and therefore, increase oxidative
metabolism (Izquierdo-Garcia et al., 2015; Whitehouse, Cooper, & Randle,
1974). We found that DCA could exert this effect on HCT116 cells, where
phosphorylation of PDH was diminished by 10-fold in DCA treated cells.
Moreover, HCT116 colorectal cells treated with DCA displayed elevated butyrate
oxidation, which is consistent with phospho-PDH playing a role in the diminished
butyrate oxidation observed in the colorectal cell. In a previous paper, Roediger
and Nance (1990) reported that addition of DCA had no effect on conversion of
14C-butyrate

to 14CO2 (WEW Roediger & Nance, 1990). This suggests that the
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increased butyrate oxidation caused by DCA, was specific for the cancer cell,
where PDH was inactivated through phosphorylation. The selective effects of
butyrate on colorectal cancer cells as opposed to non-cancerous cells may be
the result of altered cellular metabolism with inactivation of PDH at the center of
the cause through diminishment of butyrate oxidation.
To date, there have been no human studies testing the effect of carnitine
supplementation on colorectal cancer. However, dietary sources high in carnitine,
such as red meat, have been associated with an increased risk for the
development of colorectal cancer. Our data might suggest that consumption of
red meat (high in carnitine) would increase the oxidation of butyrate and
subsequently diminish HDAC inhibition. As a results of increase butyrate
oxidation, butyrate’s protective actions toward colorectal cancer would be
diminished. In addition, carnitine supplementation in humans has been shown to
increase trimethylamine-N-oxide(TMAO) in a microbiota-dependent manner
(Koeth et al., 2013). Elevated blood/plasma TMAO has been suggested to be a
causal factor in colorectal cancer (Bae et al., 2014; Xu, Wang, & Li, 2015). Thus,
carnitine supplementation may have tumor-promoting effects in humans that are
fiber-or butyrate-dependent (carnitine’s role in regulating butyrate oxidation) and
independent (formation of TMAO from carnitine).
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Figure 12 Butyrate oxidation in non-cancerous and cancerous colonocytes.
(A) Diagram showing experimental strategy that will be used to measure butyrate
oxidation in cells over time with XF24 Analyzer. (B) Percent change in oxygen
consumption rate (OCR) relative to baseline for 0.5, 1.0, 2.0, and 5.0mM butyrate
in HCT116 cells. Total contribution of butyrate toward OCR (%) is observed after
injection of 2-deoxyglucose (2DG). (C) Percentage change in OCR relative to
baseline was determined in HCT116 and FHC cells with or without butyrate
injected into the wells (final concentration of butyrate is 5mM). 2DG was then
injected into wells and butyrate oxidation was analyzed. (D) Area under the curve
analysis from OCR measurements taken after 2DG injection, but before azide
injection (80-128min). These measurements represent the butyrate oxidation
(arbitrary units), as butyrate is the only exogenous oxidative substrate available.
(E) Representative western blot of MCT1 from FHC and HCT116 cells with β- as
loading control. The glucose concentration in the in the fatty acid oxidation media
for panels B and C was kept constant at 2.5mM. Data points represent the
average OCR (%) over 3-5 replicates per experimental condition. Error bars are
+/- the SEM.
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Figure 12 continued
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Figure 13 Butyrate oxidation is carnitine -dependent and -independent.
(A) Intracellular carnitine level in FHC cells and HCT116 cells. (B) Representative
western blot showing OCTN2 expression in FHC and HCT116 cells with β-actin
serves as loading control. (C) Percent change in oxygen consumption rate (OCR)
relative to baseline in HCT116 cells treated with and without butyrate (5mM) and
carnitine (50μM). Total contribution of butyrate toward OCR (%) is observed after
injection of 2-deoxyglucose (2DG). (D) Area under the curve analysis from OCR
measurements taken after 2DG injection, but before azide injection (56-84 min).
These measurements represent butyrate oxidation (arbitrary units) at 5mM. (E)
Percent change in OCR relative to baseline in HCT116 cells treated with and
without butyrate (1mM) and carnitine (50μM). As before, total contribution of
butyrate toward OCR (%) is observed after injection of 2DG. (F) Area under the
curve analysis from OCR measurements taken after 2DG injection, but before
azide injection (56-84 min). These measurements represent butyrate oxidation
(arbitrary units) at 1mM. For butyrate oxidation measurements data points
represent the average OCR (%) over 3-5 replicates per condition. Error bars are
+/- SEM.
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Figure 13 continued
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Figure 14 Carnitine selectively affects butyrate oxidation in a dosedependent manner.
(A) Percent change in oxygen consumption rate (OCR) relative to baseline in
HCT116 cells treated with and without butyrate (5mM) and increasing carnitine
concentrations (12.5, 25, and 50μM). Total contribution of butyrate toward OCR
(%) is observed after injection of 2-deoxyglucose (2DG). (B) Area under the
curve analysis from OCR measurements taken after 2DG injection (All
measurements after 50min). These measurements represent butyrate oxidation
(arbitrary units) at 5mM with increasing carnitine concentrations. (C) Percent
change in oxygen consumption rate (OCR) relative to baseline in HCT116 cells
treated with and without SCFAs (ACE, acetate; PRO, propionate; BUT, butyrate)
and carnitine (50μM). Final concentration for all SCFAs was 5mM. (D) Area
under the curve analysis from OCR measurements taken after 2DG injection, but
before azide injection (80-108 min). These measurements represent butyrate
oxidation (arbitrary units). For butyrate oxidation measurements data points
represent the average OCR (%) over 3-5 replicates per condition. Error bars are
+/- SEM.

105

Figure 14 continued
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Figure 15 Butyrate oxidation is CPT1A dependent.
(A) Percent change in oxygen consumption rate (OCR) relative to baseline in
HCT116 cells treated with and without butyrate (5mM) and etomoxir (after 2DG
injection). Total contribution of butyrate toward OCR (%) is observed after
injection of 2-deoxyglucose (2DG). Effect toward blocking CPT1 is shown after
etomoxir injection. (B) Area under the curve analysis from OCR measurements
taken after 2DG injection, but before azide injection (82-112 min). These
measurements represent butyrate oxidation (arbitrary units) with or without
etomoxir injection. (C) Representative western blot of RNAi knockdown (siMock
and siCpt1A) showing CPT1A expression over time course of 72h. CPT1A
expression was maximally knocked down after 72h treatment. β- actin serves as
loading control. (D) Palmitate oxidation (arbitrary units) calculated from
subtraction of OCR measurements before and after etomoxir injection. (E)
Percent change in OCR relative to baseline in HCT116 cells that received siMock
or siCpt1A treated with and without 5mM butyrate. (F) Area under the curve
analysis from OCR measurements taken after 2DG injection, but before azide
injection (80-100 min). Measurements represent butyrate oxidation (arbitrary
units). For butyrate oxidation measurements data points represent the average
OCR (%) over 3-5 replicates per condition. Error bars are +/- SEM.
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Figure 15 continued
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Figure 16 Carnitine suppressed HDAC inhibition and H3 acetylation.
(A) HDAC activity as measured in HCT116 cells treated with or without butyrate
and carnitine (50μM) for 1h. Average values represent three replicates per
condition. (B) Representative western blot showing relative H3 acetylation in
HCT116 cells treated ± butyrate (1 or 5mM final concentration) and carnitine for
24h. (C) Quantification of H3 acetylation levels relative to total H3 levels. β-actin
was used as loading control. Error bars are +/- SEM.
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Figure 17 Impact of PDH inactivation on butyrate oxidation.
(A) Working model of pathways that regulate butyrate oxidation. In this model,
butyrate is oxidized by a CPT1-independent and -dependent mechanism.
Carnitine levels and CPT1 expression are both mediators of butyrate oxidation.
Decreased butyrate oxidation occurs as PDH becomes inactivated (through
phosphorylation of E1) and the Warburg effect decrease OCTN2 and the
carnitine-dependent mechanism. (B) Representative western blot showing
phospho-PDH (Ser293) and total PDH in HCT116 cells treated ± DCA (5mM) for
6h. β-actin was used as loading control. (C) Percent change in oxygen
consumption rate (OCR) relative to baseline in HCT116 cells treated with and
without butyrate (5mM) and dichloroacetate (50μM). Total contribution of butyrate
toward OCR (%) is observed after injection of 2-deoxyglucose (2DG). (D) Area
under the curve analysis from OCR measurements taken after 2DG injection, but
before azide injection (74-100 min). These measurements represent butyrate
oxidation (arbitrary units). For butyrate oxidation measurements data points
represent the average OCR (%) over 3-5 replicates per conditions. Error bars are
+/- SEM.
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Figure 17 continued
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Figure 18 Carnitine-dependent mechanism is regulated through
inactivation of PDH.
(A) Representative western blot showing CPT1A, OCTN2, phospho-PDH
(Ser293), and total PDH in HCT116 cells treated ± DCA (5mM) for 6. β-actin was
used as loading control. (B) Percent change in oxygen consumption rate (OCR)
relative to baseline in HCT116 cells treated with and without butyrate (5mM),
carnitine (50μM), and DCA. Total contribution of butyrate toward OCR (%) is
observed after injection of 2-deoxyglucose (2DG). (C) Area under the curve
analysis from OCR measurements taken after 2DG injection, but before azide
injection (88-116 min). These measurements represent butyrate oxidation
(arbitrary units). For butyrate oxidation measurements data points represent the
average OCR (%) over 3-5 replicates per condition. Error bars are +/- SEM.
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Figure 19 CPT1a expression in FHC and HCT116 cells
(A) Western blot showing CPT1A expression in FHC and HCT116 cells. (B)
Quantification of CPT1A levels relative to β-actin levels.
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CHAPTER III
BUTYRATE REGULATES ITS OWN METABOLIC FATE AS AN
HDAC INHIBITOR IN COLORECTAL CANCER CELLS
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A version of this chapter is submitted by Anna Han, Bettaieb Ahmed, Jay
Whelan, and Dallas R. Donohoe entitled “Butyrate regulates its own metabolic
fate as an HDAC inhibitor in colorectal cancer cells” in Journal of Cell Biology
(April 2017).
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3.1 Abstract
Colorectal cancer is characterized by a metabolic shift toward increased
glucose utilization. Butyrate, the major energy source for non-cancerous
colonocytes that is produced from the fermentation of fiber, is underutilized and
its role as an HDAC inhibitor is altered in cancerous colonocytes. Understanding
this metabolic shift is important in deciphering the protective effects derived from
consuming a fiber diet in colorectal cancer. We discover that butyrate itself
diminishes its own oxidation in cancerous colonocytes. This reduction in butyrate
oxidation is associated with decreased expression of acyl-CoA dehydrogenaseshort chain (SCAD) an important component that mediates the oxidation of shortchain fatty acids such as butyrate. Butyrate does not alter SCAD levels in noncancerous colonocytes. Trichostatin A, a structurally unrelated HDAC inhibitor,
and propionate also diminish SCAD alluding to HDAC inhibition as part of the
mechanism. Moreover, butyrate specifically inhibits HDAC1 to suppress SCAD
expression. Knockdown of HDAC1, but not HDAC 2 or 3 abrogated the effects of
butyrate on SCAD expression. This work identifies a mechanism by which
butyrate selective targets colorectal cancer cells through changes in metabolism.
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3.2 Introduction
Colorectal cancer (CRC) is the third most common and lethal cancer in the
United States (Siegel, Miller, & Jemal, 2016). Considering diet is one of the
strongest influential risk factors of CRC development, intervention of diet has
been suggested as an effective way to decrease CRC development and mortality
(Haggar & Boushey, 2009; Johnson et al., 2013; Vargas & Thompson, 2012).
Many studies have observed the beneficial effect of dietary fiber against CRC,
although some studies have reported contradicting findings (Bingham et al.,
2003; Dahm et al., 2010; Michels et al., 2000; Romaneiro & Parekh, 2012). The
fermentation of dietary fiber in the proximal colon produces bacterial derivedshort chain fatty acids (SCFAs) including acetate, propionate and butyrate.
Among these SCFAs, butyrate has been considered a critical metabolite that
drives the tumor repressive effects of dietary fiber against CRC (Blackwood,
Salter, Dettmar, & Chaplin, 2000; Macfarlane & Macfarlane, 2012; Scharlau et
al., 2009).
Unlike other SCFAs, butyrate is primarily metabolized by colonocytes as
an energy source and also plays a role in epigenetic modification as a histone
deacetylase (HDAC) inhibitor (Donohoe et al., 2011; Hamer et al., 2008; Steliou,
Boosalis, Perrine, Sangerman, & Faller, 2012). At physiologically relevant doses,
butyrate regulates cell proliferation, differentiation and apoptosis in colorectal
cancer cells (Archer et al., 2005; Davie, 2003; Hinnebusch, Meng, Wu, Archer, &
Hodin, 2002). Interestingly, the role butyrate plays in cell proliferation and
apoptosis is related to its metabolic fates in colonocytes (Andriamihaja,
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Chaumontet, Tome, & Blachier, 2009; Donohoe, Collins, et al., 2012). In normal
colonocytes, butyrate is oxidized through mitochondrial β-oxidation and then
utilized to produce energy through the tricarboxylic acid (TCA) cycle or cytosolic
acetyl-CoA. This acetyl-CoA can be used as a cofactor for histone
acetyltransferases (HATs) or substrates for lipogenesis (Donohoe, Collins, et al.,
2012; Rémésy, Demigne, & Morand, 1992). However, cancerous colonocytes
favor glucose over butyrate utilization as a result of a metabolic transformation
called the Warburg effect. This glucose-preferred environment results in
suppressed oxidation and elevated cellular butyrate levels, which help promote
its action as an HDAC inhibitor (Andriamihaja et al., 2009; Donohoe, Collins, et
al., 2012). Therefore, to understand butyrate’s inhibitory and selective effect
against CRC, the investigation regarding butyrate metabolism in cancerous
colonocytes is crucial.
Short chain acyl-CoA dehydrogenase (SCAD) is an enzyme that catalyzes
the first step of butyrate mitochondrial β-oxidation in the cells (M Astbury & M
Corfe, 2012). SCAD deletion reduces butyrate catabolism whiles simultaneously
increasing butyryl-CoA accumulation and excretion, illustrating its role in butyrate
metabolism (Augenlicht et al., 1999; Bhala et al., 1995; Wood et al., 1989).
Additionally, the removal of SCAD in colonocytes leads to actual decreasing of
butyrate oxidation (Kaiko et al., 2016). Previous studies have observed reduced
protein expression related to mitochondrial metabolism in CRC including SCAD
at both mRNA and protein levels (Birkenkamp-Demtroder et al., 2002; Jankova et
al., 2011; Kim et al., 2006; Kitahara et al., 2001). However, there little is known
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about the mechanism that controls SCAD expression. In this study, we report
that butyrate regulates its own metabolism in colorectal cancer cells through
suppressing SCAD expression. The mechanism as to how butyrate impacts
SCAD levels in colorectal cancer cells is explored and appears to be mediated
through HDAC inhibition. Importantly, non-cancerous colonocytes do not show
this effect, thus it is selective to colorectal cancer cells.

3.3 Materials and Methods
3.3.1. Cell culture and siRNA transfection
HCT116 cell (ATCC, CCL-247) were grown in DMEM supplemented with
25mM glucose and 10% FBS. FHC cells (ATCC, CRL-1831) were grown in
complete growth DMEM:F12 medium following the recommended recipe from
ATCC with 20% FBS. RNAi transfection in HCT116 cells was performed as
previously described (Donohoe, Collins, et al., 2012), and siRNA pools for human
ACL (Dharmacon, #L-004915-00), human HDCA1 (Dharmacon, #L-003493-000005), human HDAC2 (Dharmacon, #L-003495-02-0005), human HDCA3
(Dharmacon, #L-003496-00-0005) and non-targeting control (Dharmacon,
D001810-01-05) were used at a 20mM final concentration. The optimized time
for each siRNA transfection was confirmed with Western blotting.
3.3.2. Colonocytes isolation
C57B1/6J were purchased from Jackson Laboratories (Bar Harbor, ME)
and were maintained on a 12-hour light-dark cycle with free access to wather and
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standard laboratory chow (Purina lab chow, Cat # 5001). Mouse studies were
conducted according to federal regulations and were approved by the
Institutional Animal Care and Use Committee at the University of TennesseeKnoxville. Isolation of colonic epithelial cells from mice were performed from 8-12
weeks old male mice as previously described (Donohoe, Wali, Brylawski, &
Bultman, 2012). Colons were washed several times with sterilized phosphatebuffered saline (PBS). Then, the colon was incubated in PBS containing 5 mM
EDTA (Fisher Scientific, Cat# S311-500) and 1% FBS, with or without butyrate (5
and 10 mM), for 45 mins at 37 ℃. After 45 mins, the tissues were removed and
isolated colonocytes were collected through centrifugation
3.3.3. Biochemical Assays
HDAC activity assay was performed according to manufacturer
specifications (BioVision, Cat# K339-100). Briefely, HCT116 cells seeded into
96well plates and treated with butyrate (Sigma, B5887) and trichostatin A
(Promega, G6560). Following treatment times, assay was performed. All values
were normalized to total protein in each well.
3.3.4. Flux experiment
To measure percentage change of oxygen consumption rates (% OCR) in
HCT116 cells, Seahorse XF24 Analyzer (Seahorse Bioscience) was used. All
Seahorse assays were conducted according to the company guidelines, and the
experimental design to measure butyrate oxidation in HCT116 cells were
followed as stated (Han et al., 2015). HCT116 cells were seeded into XF24 cell

120

culture microplates (Seahorse Bioscience, 100777-004) with an identical cell
number per well. Cell plates are incubated with 1X KHB (2.5 mM glucose and 50
μM carnitine) in non-CO2 incubator at 37℃ for one hour before Seahorse assay.
All Seahorse experiments were performed with identical conditions (unless
otherwise stated). In brief, KHB media or sodium butyrate (Sigma, B5887) at 5
mM final concentration were injected and the change in OCR was measured
from baseline (% OCR). Then, 2-deoxyglucose (Sigma, D8375) was injected
and % OCR was measured again. At last, 10% sodium azide was injected to
block mitochondrial respiration by inhibiting complex IV, hence after azide
injection OCR decreased at or below baseline respiration.
3.3.5 Western blot
From FHC, HCT116 cells and isolated colonocytes, the proteins are
extracted with RIPA buffer (Cell Signaling, #9806), 1mM PMSF (Cell Signaling,
#8553) and phosphatase inhibitor cocktail (Cell Signaling, #5872).
Quantifications of protein were measured by Bradford assay. Gel electrophoresis
and transfer were performed using standard protocol for Western blotting.
Antibodies that were used included pan-acetylated-histone H3 (Active motif, Cat#
39139), total Histone H3 (Active motif, Cat# 39763), total PDH (Abcam, Cat#
ab110330), ACL (Cell Signaling, Cat # 4332), SCAD (Abcam, Cat# 154823),
HDAC1 (Cell signaling, Cat# 34589), HDAC2 (Cell signaling, Cat# 57156),
HDAC3 (Cell signaling, Cat# 85057) and β-actin (Sigma, Cat# A1978).
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Chemiluminescence detection was conducted with the Odyssey Fc and bands
were quantified with Image Studio Software (LI-COR Biosciences, Lincoln, NE).
3.3.6. mRNA expression
Total RNA from (un) treated HCT116 cells were extracted using Trizol
reagent (ambion, Cat# 15596-026). The concentration and integrity of RNA were
measured by Nano-drop 1000. Reverse transcription was performed with
RevertAid RT kit (Thermo Scientific, Cat# K1691) by following the company’s
protocol. The amounts of product from RT-qPCR was measured by SYBR Green
fluorescence (applied Biosystems, Cat# 4309155). SCAD primers for isoform 1
(Forward: GCGACTCATGGGTTCTGAAT and Reverse:
TGCGACAGTCCTCAAAGATG), isoform 2 (Forward:
GCCCGACTGGACCTATTTTT and Reverse: TGCGACAGTCCTCAAAGATG)
and total (Forward: CAGGGATGGGCTTCAAGATA and Reverse:
TGTCTGCCAACTTGAACTGG) were designed and their efficiency was
confirmed by gel PCR. Relative gene expression levels were calculated through
the ΔΔ Ct method and normalized to human 18S rRNA.
3.3.7. Statistical analysis
For biochemical assays, Seahorse experiments, and Western blotting, the
differences between experimental groups were determined by ANOVA followed
by a Tukey post-hoc test. All data are expressed as mean ± SEM. Groups are
considered significantly different at p < 0.05.
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3.4 Results
3.4.1. Butyrate diminishes its own oxidation by inhibiting SCAD expression
in colorectal cancer cells
In recent years our lab has sought to identify factors or conditions that
impact the oxidation of butyrate in colorectal cancer cells. Since butyrate
modulates gene expression through inhibiting HDACs, we postulated that
butyrate could directly affect its own metabolic fates. To begin to test this
possibility, HCT116 colorectal cancer cells were pretreated with or without
butyrate (5 mM). Then, the percentage change in oxygen consumption rate (%
OCR) was measured after 24 hours. In pretreated cells, butyrate repressed its
own oxidation (Figure 20A). In order to inhibit glucose oxidation resulting in OCR
values only contributed by butyrate, 2-deoxyglucose (2DG), which blocks glucose
utilization was injected. After 2DG injection, butyrate oxidation was significantly
lower in pretreated cells as compared to non-pretreated controls (Figure 20B).
Butyrate is transported into the colonocyte via a monocarboxylate transporter-1
(MCT1), where it taken up into the mitochondria and oxidized through carnitinedependent and independent mechanisms (Han et al., 2015). After butyrate
moves into the mitochondria, short chain acyl-CoA dehydrogenase (SCAD)
catalyzes the first dehydrogenation step of butyryl-CoA to produce acetyl-CoA (M
Astbury & M Corfe, 2012) (Figure 20C). Western blot analysis of colorectal
cancer cells showed that butyrate suppressed the expression of SCAD (Figure
20D).
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3.4.2. Butyrate reduces SCAD expression only in colorectal cancer cells
Butyrate decreased the expression of SCAD in colorectal cancer cells;
however, it was not clear whether butyrate would have this same effect in noncancerous colonocytes. Cancerous colonocytes have a reduced ability to oxidize
butyrate compared to non-cancerous colonocytes which result in part from lower
cellular carnitine levels and reduced protein expression related to carnitinedependent mechanisms, such as organic cation/carnitine transporter, OCTN2
and carnitine palmitoyltransferase, CPT1A (Han et al., 2015). Thus, the reduced
ability of cancerous colonocytes to oxidize butyrate may be due to the reduced
SCAD levels compared to the non-cancerous colonocytes. To begin to address
this, we compared SCAD levels in cancerous (HCT116 cells) and non-cancerous
(FHC cells) colonocyte lines. To our surprise, SCAD expression was actually
higher in HCT116 cells than FHC cells (Figure 21A). This may be due to the fact
that the expression and activity of enzymes that related to fatty acid metabolism
(i.e. SCAD) are dramatically elevated after birth in tissues that strongly
metabolize fatty acids (Nagao, Parimoo, & Tanaka, 1993). Since FHC cells
originated from a 13-week fetus, we concluded that the FHC cells are not a
representative cell line for non-cancerous colonocytes. However, using a primary
colonocytes, Kaiko et al. (2011) confirmed that normal colonocytes have high
SCAD expression compared to the stem cells in the colonic crypts (Kaiko et al.,
2016).
Cancerous colonocytes increase aerobic glycolysis (utilize the Warburg
effect), which may after the expression of proteins such as SCAD and impact the
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oxidation of butyrate. To directly test the importance of the Warburg effect in
butyrate-mediated SCAD reduction, we cultured cells in media with varying
glucose concentrations; high (25 mM) or low (0.5 mM). Lower SCAD expression
was observed in the HCT116 cells under both high (the Warburg effect) and low
glucose condition (suppressed the Warburg effect) (Figure 21B and Figure 25).
However, only high glucose condition led to a significant decrease in SCAD
expression (Figure 21B and 21C). Throughout this paper (unless otherwise
mentioned), pyruvate dehydrogenase (PDH) is used as a loading control instead
of β-Actin due to the fact that PDH is also a mitochondrial protein like SCAD, and
its expression is not affected by butyrate in cancerous colonocytes. Based on the
importance of the Warburg effect, non-cancerous colonocytes were isolated from
C57BL/6J wild type mice to test whether butyrate’s influence SCAD expression in
normal colonocytes that are not undergoing the Warburg effect. While butyrate
decreases SCAD expression in the colorectal cancer cells, normal isolated
colonocytes showed a trend toward increasing SCAD expression, but this was
not statistically significant (Figure 21D and 21E). Since butyrate also increases
PDH expression in the normal isolated colonocytes, we normalized SCAD
expression with β-Actin (Figure 26).
To confirm whether butyrate suppressed SCAD at the mRNA level, we
conducted qRT-PCR with all isoforms of Scad (Scad1 and Scad2) and total
Scad. At a high dose (5 mM), butyrate significantly reduced mRNA levels for
Scad1, Scad2, and total Scad in HCT116 cells (Figure 22). Additionally, at a low
butyrate concentration (1 mM), Scad2 and total Scad mRNA levels were
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significantly decreased. These data suggest that butyrate suppresses SCAD
expression at the transcriptional levels in the colorectal cancer cells, which may
involve HDAC inhibition.
3.4.3. Butyrate mediates SCAD expression as an HDAC inhibitor, not as a
metabolite
The fermentation of dietary fiber in the colon produces additional SCFAs,
which include acetate and propionate. Therefore, we sought to investigate
whether these other SCFAs reduced SCAD expression in colorectal cancer cells
like butyrate. Both propionate and butyrate significantly suppress SCAD
expression, while acetate does not influence SCAD expression in HCT116 cells
(Figure 23A and 23B). Along with butyrate, propionate has been shown to be an
HDAC inhibitor (Aoyama, Kotani, & Usami, 2010). This alludes to HDAC
inhibition as a key component in regulating SCAD expression in colorectal cancer
cells.
Butyrate is involved in epigenetic modifications through two mechanisms
(Figure 23C) (Donohoe, Collins, et al., 2012). Mitochondrial butyrate oxidation
results in the biogenesis of Acetyl-CoA, which can be utilized as a cofactor for
HATs through ATP-citrate lyase (ACL). In addition, butyrate directly goes into the
nucleus where it functions as an HDAC inhibitor. First, to test the importance of
HDAC inhibition, a structurally distinct HDAC inhibitor, trichostatin A (TSA), was
used as a positive control. Both butyrate and TSA significantly reduced SCAD
expression (Figure 23D and 23E). Next, a siRNA knockdown of ACL was
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performed and SCAD expression was evaluated with and without butyrate. Since
ACL catalyzes the reaction that converts citrate into acetyl-CoA in the cytosol, an
ACL knockdown would block butyrate’s involvement as a HAT cofactor.
However, knockdown of ACL did not impact SCAD suppression caused by
butyrate, indicating that this mechanism is unrelated to SCAD regulation. There
was no difference in the percentage change in OCR between siMock and siACL
transfected cells (Figure 27A and 27B). In addition, ACL knockdown did not alter
SCAD expression compared to siMock HCT116 cells, while butyrate still
significantly reduced SCAD expression in the both conditions (Figure 27C).
Taken together, this data point to HDAC inhibition as the major mechanism as to
how butyrate regulates SCAD expression in the colorectal cancer cells.
3.4.4. Butyrate decreases SCAD levels through selective inhibition of
HDAC1 in colorectal cancer cells
In CRC, HDAC 1, HDAC 2, and HDAC 3 are highly expressed in order to
accelerate cell proliferation, growth and survival (Weichert et al., 2008; Wilson et
al., 2006). In general, butyrate effectively inhibits most HDACs resulting in
decreased cell proliferation and induction of cell apoptosis in the cancer cells
(Davie, 2003; Donohoe, Collins, et al., 2012). Although we found that butyrate
suppresses SCAD levels through HDAC inhibitor action, it was still unclear
whether a specific HDAC was involved in regulating SCAD level. Therefore,
HDAC1, HDAC2, or HDAC3 were knocked down by RNAi and these cells were
treated with butyrate to test whether butyrate-induced SCAD reduction was
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augmented with each selective knockdown condition. While butyrate and TSA
significantly decreased SCAD levels in siMock cells, siHDAC1 transfected cells
did not shown decreased SCAD levels after butyrate treatment (Figure 24A and
24B). RNAi knockdown of HDAC2 and HDAC3 in HCT116 cells did not impact
SCAD levels like as HDAC1 (Figure 28). These findings demonstrate that
butyrate targets HDAC1 to suppress SCAD levels in the colorectal cancer cells.

3.5 Discussion
Normal colonocytes prefer to oxidize butyrate as a primary energy source
whereas cancerous colonocytes increases glucose utilization, which is
demonstrated through increased flurodeoxyglucose (FDG) uptake as measured
by Positron Emission Tomography – Computed Tomography (PET-CT) (de
Geus-Oei et al., 2006; Delbeke & Martin, 2011; Miles, 2015; Roediger, 1980). In
addition, colorectal cancer cells display a reduced capacity to oxidize butyrate
compared to normal colonocytes, which could result from diminished intracellular
carnitine, and CPT1A levels (Han et al., 2015). These metabolic alterations
significantly impact butyrate’s role as an HDAC inhibitor in colorectal cancer
(Donohoe, Collins, et al., 2012). As an HDAC inhibitor, butyrate represses cell
proliferation and induces cell death in colorectal cancer cells (Archer et al., 2005;
Archer, Meng, Shei, & Hodin, 1998; Medina et al., 1997). Thus, gaining
knowledge toward the mechanisms that regulate butyrate oxidation in cancer
cells is an important step in understanding butyrate’s role as an HDAC inhibitor,
which is associated with protective action of butyrate against CRC. Here, we
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demonstrated that butyrate suppresses its own oxidation in cancerous
colonocytes through the regulation of SCAD levels, a critical enzyme in the
oxidation of butyrate. Butyrate decreases SCAD levels as an HDAC inhibitor.
Specifically, SCAD is regulated via HDAC1.
Many studies have reported the role of SCAD in regulating butyrate
oxidation (Bhala et al., 1995; M Astbury & M Corfe, 2012; Wood et al., 1989).
SCAD contributes to energy maintenance in the colon via participating in SCFA
oxidation (Augenlicht et al., 1999). Recently, it was reported that colonocytes
isolated from SCAD-/- mice showed diminished butyrate oxidation compared to
those from control WT mice (SCAD+/+), which confirms the importance of SCAD
in mediating butyrate oxidation in colonocytes (Kaiko et al., 2016). In contrast to
this study, a cancerous colonocyte cell line was used due to previous reports
demonstrating diminished butyrate oxidation in this cell line (Donohoe, Collins, et
al., 2012; Han et al., 2015). The fact that butyrate reduces its own oxidation in
these cells reveals a potential mechanism as to why colorectal cancer cells are
sensitive to butyrate’s HDAC inhibitory effects.
This mechanistic relationship between butyrate and SCAD in the
colorectal cancer cells was significantly influenced by the Warburg effect.
Previously, it was found that butyrate (1 mM) increased SCAD expression in a
colorectal cancer cell line (HT15), however similar to a non-cancerous cell line,
these cells still preferentially utilized butyrate over glucose thereby negating the
impact of the Warburg effect (Serpa et al., 2010). The colonic administration of
butyrate in healthy subjects increases gene transcription relating to energy
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metabolism and fatty acid metabolism, while SCAD was not altered (Vanhoutvin
et al., 2009). Germfree mice, which lack a microbiome and the capability to
produce butyrate from fiber, show reduced SCAD expression compared to
normal mice (Donohoe et al., 2011). Their findings are consistent with butyrate
modulating SCAD levels differently in non-cancerous colonocytes.
In general, butyrate inhibits most HDACs, except class 2 (HDAC 6 and 10)
and class 3, and specifically inhibits HDAC 1 and 3 in colorectal cancer cells
(Davie, 2003; Thangaraju, Carswell, Prasad, & Ganapathy, 2009). As an HDAC
inhibitor, butyrate effectively impedes cancer cell survival and growth (Bultman,
2014; Davie, 2003). In addition, butyrate suppresses intestinal inflammation and
oxidative stress, while also protecting the intestinal epithelial barrier via its HDAC
inhibitor roles; there are likely to help reduce CRC susceptibility (Canani, Di
Costanzo, & Leone, 2012; Leonel & Alvarez-Leite, 2012; Plöger et al., 2012).
Separate from the non-cell autonomous effects, butyrate availability can
influence cancerous colonocyte metabolism and HDAC inhibition. The
suppressive action of butyrate on SCAD expression and its own oxidation in the
colorectal cancer cells is mediated by its function as an HDAC inhibitor. Butyrate
specifically inhibits HDAC1 to have these regulatory actions as knockdown of this
protein negates any changes in SCAD caused by butyrate. These data also
allude to butyrate promoting its own action as an HDAC inhibitor in colorectal
cancer cells through altering suppressing its own metabolism. It will be
interesting to conduct further research regarding why butyrate behaves in this
way and whether this mechanism helps mediate its specificity toward cancer
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cells. CRC (all stages) has altered gene expression characterized by lower
mitochondrial metabolism and a down-regulation in SCAD expression
(Birkenkamp-Demtroder et al., 2002; Kitahara et al., 2001). Future studies are
need to investigate the outcome of reduced SCAD expression in cancerous
colonocytes especially as it relates to the Warburg effect and diminished butyrate
oxidation.
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Figure 20 Butyrate suppresses its own oxidation by inhibiting SCAD
expression in colorectal cancer cells.
(A) Percentage change in oxygen consumption rate (OCR) relative to baseline in
pre-treated HCT116 cells with and without butyrate (5 mM, 24 hrs). (B) Area
under the curve measurement from OCR analysis taken after 2DG injection but
before azide injection (56-104 min). (C) Schematic diagram of butyrate oxidation
in the cancerous colonocytes. Cancerous colonocytes oxidize butyrate through
carnitine-dependent and/or independent pathway. In the mitochondria, SCAD
plays a role in first step of butyrate β-oxidation. (D) Western blot confirming the
reduced SCAD level by butyrate. Data for butyrate oxidation measurement
represent the average OCR (%) over 3-5 replicates per condition. Error bars are
± SEM. MCT1; monocarboxylate transport protein 1, OCTN2; organic
cation/carnitine transporter, ACSS; Acyl Co-A synthetases, CPT1/2; carnitine
palmitoyltransferase 1/2, SCAD; short chain acyl-CoA dehydrogenase
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Figure 20 continued
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Figure 21 Butyrate reduces SCAD expression in colorectal cancer cells.
(A) Western blot showing SCAD expression in FHC cells (non-cancerous
colonocytes) and HCT116 cells (colorectal cancer cells). (B) Western blot
describing SCAD expression in FHC cells and HCT116 cells that were treated
with (0 mM, CON) or without butyrate (5 mM, B5). HCT116 cells were grown
under the absence (2.5 mM glucose) and presence (25 mM glucose) for the
Warburg effect. (C) Quantification of SCAD levels relative to PDH levels. (D)
Western blot showing SCAD levels in isolated normal colonocytes with butyrate
(0 mM, CON; 5 mM, B5 and 10 mM. B10). (E) Quantification of SCAD expression
relative to β-actin levels. For statistical analysis, western blot was conducted
three times per condition. Error bars are Mean ± SEM. *p<0.05 indicates
significant difference between cells treated with butyrate Vs controls.
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Figure 21 continued

141

Figure 22 Butyrate reduces the mRNA levels of SCAD in colorectal cancer
cell.
(A) mRNA expression of isoform 1, isoform 2 and total SCAD was evaluated by
semi-quantitative RT-PCR (0 mM, CON; 5 mM, B5 and 10 mM, B10). The
relative mRNA level was normalized to 18S rRNA and shown as fold of the
control value. For statistical analysis, qRT-PCT was conducted three times per
condition. Error bars are Mean ± SEM. *p<0.05 and **p<0.01 indicates significant
difference between cells treated with butyrate Vs controls.
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Figure 23 Butyrate mediates SCAD expression as an HDAC inhibitor in
colorectal cancer cells
(A) Western blot showing SCAD expression in HCT116 cells that were treated
with a set of SCFAs (ACT; acetate, PRO; propionate, BUT; butyrate and APB; all
of SCFAs) at 5 mM. (B) Quantification of SCAD levels relative to PDH levels. (C)
A figure of mechanisms that butyrate plays in epigenetic role in colonocytes. In
this figure, butyrate acts as a co-factor for HATs through the involvement of ATPcitrate lyase (ACL). Also, butyrate directly inhibits HDACs. (D) Western blot
describing SCAD expression in HCT116 cells that were treated with butyrate (5
mM) or TSA (1 μM). (E) Quantification of SCAD expression relative to PDH
levels. For statistical analysis, western blot was conducted three times per
condition. Error bars are Mean ± SEM. *p<0.05 and **p<0.01 indicates significant
difference between cells treated with butyrate Vs controls.
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Figure 23 continued
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Figure 24 Butyrate selectively inhibits HDAC 1 to reduce SCAD expression
in colorectal cancer cells.
(A) Western blot showing SCAD expression in siMock and siHDAC1 transfected
HCT116 cells after treatment without butyrate and with butyrate (5 mM) or TSA
(1 μM) for 6hrs. (B) Quantification of SCAD levels relative to PDH levels. For
statistical analysis, western blot was conducted three times per condition. Error
bars are Mean ± SEM. *p<0.05 indicates significant difference between cells
treated with butyrate Vs controls.
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Figure 25 The Warburg effect involves in SCAD levels in colorectal cancer
cells.
(A) Western blot showing SCAD expression in FHC cells (non-cancerous
colonocytes) and HCT116 cells (colorectal cancer cells) with or without Warburg
effect. (B) Quantification of SCAD levels relative to PDH levels. For statistical
analysis, western blot was conducted three times per condition. Error bars are ±
SEM.
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Figure 26 Butyrate increases PDH levels in normal isolated colonocytes.
Quantification of PDH expression relative to β-actin levels. For statistical
analysis, western blot was conducted three times per condition. Error bars are ±
SEM.
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Figure 27 Butyrate does not regulate SCAD expression as a metabolite in
colorectal cancer cell.
(A) Percent change of oxygen consumption rate (OCR) relative to baseline in
siACL and siMock transfected HCT116 cells. OCR (%) after 2DG injection is total
contribution of butyrate. (B) Area under the curve analysis from percentage
change in OCR of siMock and siACL transfected HCT116 cells with and without
butyrate (5 mM). OCR measurement taken after 2DG injection, but before
etomoxir (ETO) injection (48-72 mins) (C) Western blot presenting SCAD levels
siMock and siACL transfected HCT116 cells after treatment of butyrate or not.
Data for butyrate oxidation measurement represent the average OCR (%) over 35 replicates per condition. Error bars are ± SEM. For statistical analysis, western
blot was conducted three times per condition. Error bars are Mean ± SEM.
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Figure 28 HDAC 2 and HDAC 3 are not involved in SCAD suppression by
butyrate in colorectal cancer cells.
(A) Western blot presenting SCAD levels in siMock and siHDAC2 transfected
HCT116 cells after treatment without butyrate and with butyrate (5 mM) or TSA
(1 μM) for 6 hrs. (B) Quantification of SCAD levels relative to PDH levels. (C)
Western blot showing SCAD levels in siMock and siHDAC3 transfected HCT116
cells after pre-treatment without butyrate and with butyrate (5 mM) or TSA (1
μM). (D) Quantification of SCAD levels relative to PDH levels. For statistical
analysis, western blot was conducted three times per condition. Error bars are
Mean ± SEM. *p<0.05 indicates significant difference between cells treated with
butyrate Vs controls.
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CONCLUSION AND FUTURE DIRECTION
In this dissertation, it has been presented (1) the capacity of butyrate
oxidation is reduced in cancerous colonocytes compared to non-cancerous
colonocytes; (2) butyrate is oxidized in the colorectal cancer cells by both a
carnitine-dependent and -independent mechanisms at physiologically relevant
levels, which are selective for butyrate only among other SCFAs oxidation; (3)
carnitine-dependent butyrate oxidation mechanism is suppressed in colorectal
cancer cells through PDH inhibition; (4) butyrate decreases its own oxidation by
suppressing SCAD expression in cancerous colonocytes; (5) butyrate functions
as an HDAC inhibitor and selectively inhibits HDAC 1 in order to reduce SCAD
levels and its own oxidation in colorectal cancer cells .
Our findings bring a better understanding of butyrate metabolism in
cancerous colonocytes that allows insight into why butyrate has selective and
inhibitory effects against colorectal cancer cells. Moreover, we report here for the
first time that butyrate is involved in its own oxidation by specifically inhibiting
HDAC1.
In the future, the studies of the effect of carnitine supplementation on
colorectal cancer by using animal model and/or human study would be needed to
test the results using in vitro models suggested in chapter II. Dietary sources with
high carnitine (i.e. red meat) have shown an increased susceptibility of CRC
development. Based on our findings in chapter II, the consumption of high
carnitine dietary sources (i.e. red meat) might increase butyrate oxidation
resulting in reduced HDAC inhibition and subsequently reduce butyrate’s
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protective effects against CRC. Successful animal and/or human studies will offer
a justification of butyrate’s selective and protective effects toward CRC.
Moreover, based on the conclusions of chapter III, we need to answer why
butyrate regulates its own oxidation in cancerous colonocytes. This future studies
will suggest another mechanism whereby butyrate shows anti-cancer effects
toward CRC. Also, investigating role of SCAD in butyrate oxidation in cancerous
colonocytes would be helpful to explain why cancerous colonocytes have
reduced butyrate oxidation capability compared to non-cancerous colonocytes
and its subsequent results in colorectal cancer development.
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